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ABSTRACT

Pharmacological and Behavioral Treatments for
Migraine Headaches: A Meta-Analytic Review

by

Kristi Lowe Stewart , Doctor of Philosophy
Utah State University, 2004

Major Professor: Dr. Kevin Masters
Department: Psychology

Migraine headache is a painful and often serious problem in the United States .
There are many prophylactic pharmacological and nonpharmacological treatments
available for migraine headaches . However , choosing between them can be difficult for
individuals and treatment providers alike. The primary literature regarding the
effectiveness of pharmacological and nonpharmacological treatments is quite dense. More
than 191 primary studies were identified as providing information about the effectiveness
of one or more treatments for migraine headaches. Of these, 82 articles were retained for
meta-analyses on six prophylactic treatments for migraine: propranolol, flunarizine,
divalproex sodium, thermal biofeedback, relaxation treatments, and combined treatments.
These results suggest that all of the treatments examined have very similar treatment effect
sizes. Effect sizes for the reduction of migraine were found to be between .60 and .75 for
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all treatments. Results suggest that selection of treatment for migraine must be based on
more than treatment effectiveness rates alone.
(200 pages)
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CHAPTER I
PROBLEM STATEMENT

Recurrent headaches are a problem for millions of men and women (Goldstien &
Chen, 1982). One type of headache, the migraine, is a disabling syndrome resulting in
significant life impairment (Unruh, 1996). There are two categories of treatments for
migraine headaches . The first, pharmacological treatments, encompasses several classes of
agents that are used in the treatment of headache pain including beta-adrenergic blockers,
calcium channel blockers, and anticonvulsants (Solomon , 1995). The second category of
treatments for migraine headaches are nonpharmacological. These include thermal and
electromyograph (EMG) biofeedback , relaxation training, and cognitive techniques
(Capobianco , Cheshire, & Campell, 1996).
The primary literature regarding the effectiveness of pharmacological and
nonpharmacological treatments is quite dense. More than 191 primary studies were
identified as providing information about the effectiveness of one or more treatments for
migraine headaches. A majority of these primary studies (approximately 65%) compared
their active treatment to a placebo or control group. Of those that did compare to other
active treatments only three compared pharmacological and nonpharmacological
treatments in the same study. While control group research comparisons give valuable
information regarding whether the treatments are better than no treatment, this type of
research design does little to inform about comparative effectiveness. As a result, there are
at least 16 different categories of treatments with some empirical evidence supporting their
use, but little data indicating which are the "better" treatments. Obviously, sorting through
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this amount of information arrd selecting the most effective treatment can be
overwhelming.
Attempts have been made to synthes12e the effectiveness literature for migraine
headaches through reviews. However, most of the existing reviews narrowly focus on
either pharmacological or nonpharmacological treatments. There are two existing reviews
that evaluated both pharmacological and nonpharmacological treatments for migraine
headaches in adult populations (Holroyd & Penzien , 1990; Duke University and the
Center for Clinical Health Policy Research, 1999a, 1999b) . The first (Holroyd & Penzien,
1990) examined 73 primary studies , however, it examined only one pharmacological
treatment (Propranonol) and two nonpharmacological treatments (relaxation and
relaxation/biofeedback). Statistical methods (percent improvement) used in this metaanalysis are unfocused estimations of effect and are not standardized. In addition, since the
Holroyd review (which collected data through 1989), there have been several new studies
published that examine the effectiveness of treatments for migraine headaches.
The second review consisted of two sections of review developed by the Agency
for Health Care Policy and Research (Duke University, Center for Clinical Health and
Policy Research , 1999a, 1999b). This review was published after the proposal date of the
current project and it mirrors many of the current authors intentions. The first part of the
Duke University (1999a) review synthesized the data for behavioral and physical
treatments for migraine. This methodologically sophisticated review was excellent in most
aspects. The second part of the review (1999b) synthesized the data for prophylactic
pharmacological agents for migraine. The review only included randomized controlled
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trials of pharmacological, psychological, behavioral and physical (e.g., acupuncture)
treatments. However, this meta-analysis did not compare the findings between
pharmacological and nonpharmacological groups. Of interest was the authors ' choice in
this review to include the percent improvement measure in the nonpharmacological data
and not in the pharmacological data. This was curious given their emphasis on consistency
of evaluation methods across domains. In addition, the results have not been published
(likely due to length and complexity) outside of the National Technical Information
Service (NTIS). Therefore , the area of migraine headaches is without an easily accessible
comprehensive review of the primary research literature .
The lack of synthesis of the literature between two supposedly empirically
supported categories of treatment made it difficult to determine which, if any, of the
treatments were most effective. It is important to understand how pharmacological and
nonpharmacological treatments compare to one another so that practitioners and
consumers can make informed choices. Therefore , a new meta-analytic review needed to
be conducted that integrated the data from both pharmacological and nonpharmacological
research. A single integrative review of the effectiveness findings for migraine will serve as
a valuable resource for information regarding recurrent headaches and will fill a void that
exists in the research literature. This project endeavored to fill this void by conducting
meta-analyses on six prophylactic treatments for migraine and comparing them to one
another.

4
CHAPTER II
REVIEW OF THE LITERATURE

Introduction

This review of the literature begins with a brief overview of migraine headaches,
other related recurrent headaches syndromes, and their treatments. Recurrent headaches
are a problem for millions of Americans and many treatment options are available.
However, this review of migraine headaches and the two treatment categories available
(pharmacological and nonpharmacological) will illustrate that the sheer number of
available treatment choices can create decision-making difficulties for professionals and
consumers alike. It is suggested that what is needed in the area of migraine headache
treatment research is a synthesis of the data and a comparison of effectiveness rates across
categories. One option to meet this need, a meta-analysis, is presented. Previous reviews
on the topic are then explored to examine where previous meta-analyses have succeeded
and failed. In addition, previous reviews are examined to develop guidelines for a
proposed meta-analytic review.

Recurrent Headache Syndromes

While most people experience mild headaches from time to time, millions of people
each year are affected by disabling headaches (Holroyd & French, 1995). New cases of
disabling recurrent headaches are estimated to occur at nearly two million per year;
making recurrent headaches a serious health problem in the United States (Goldstein &
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Chen, 1982). Recurrent headaches are not a homogenous group of symptoms. Rather, a
recent classification system identified 12 diagnostic categories with 145 subcategories of
headaches (Headache Classification Committee of the International Headache Society
[IHS], 1988). The 12 major diagnostic categories can be broken into three basic types of
headaches: migraine, tension, and mixed type. Each type of headache is associated with
specific symptom profiles. These profiles help make headache syndromes distinct from one
another. This review is primarily interested in exploring migraine headache syndrome.
Therefore, this section presents the symptom profile, the prevalence, and the etiology of
migraine headache syndrome. It is necessary, however, to establish a general
understanding of the full range of other recurrent headache syndromes (tension and mixed)
to evaluate how migraine headaches relate to these other syndromes. Thus, tension
headache and mixed-type headache will also be briefly described in this section. Then in
the following section, treatment modalities for migraine headache syndrome will be
explored.

Migraine Headaches
Migraine headaches are characterized by severe periodic pulsating headaches
which can range in duration from a few minutes to three days. Migraines have unilateral
locations (occur on one side of the head) and are often associated with severe pain, light
avoidance, sound avoidance, and vomiting (Taylor, 1991). Migraines have been noted to
occur in distinct phases (Blau, 1980). The phases that have typically been identified are the
prodrome, aura, headache, resolution, and postdrome. The prodrome phase can occur
several hours or days before the onset of the headache phase and can serve as a warning of
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an oncoming migraine (Capobianco et al., 1996). Symptoms of the prodrome phase
include osmorphobia, photophobia , drowsiness, euphoria, irritability, and food cravings.
The aura phase occurs immediately prior to the migraine attack. The symptoms associated
with the aura typically last less than an hour and consist of visual disturbances, numbness
in limbs, and/or language disorders (Capobianco et al.). The headache phase is typically
characterized by unilateral pulsating head pain that lasts for 4 to 72 hours (Holyroyd &
French, 1995). Pain diminishes during the resolution phase and during the postdrome
phase pain is eliminated and all symptoms vanish. The term migraine refers to a headache
that includes any or all of these phases. It is customary to distinguish between "classic
migraines ," which include a prodrome or aura phase, and "common migraines," which do
not.
Migraine suffers often experience their first episode in childhood or adolescence,
although onset in the 20s or 3-s is not uncommon. The later the onset of the headache the
more likely it is to be associated with organic cause (e.g., cerebrovascular disease or
tumor; Dalessio, 1994). In a review of the literature on migraine prevalence Stewart,
Schecter, and Rasmussen (1994) reported that migraine occurs most commonly in
individuals between the ages of25 and 50. The authors also reported that lifetime
prevalence rates have been reported in the literature to range from 8-42% of the
population. Estimates of prevalence vary widely by how migraine headache is defined and
diagnosed. According to Stewart et al., studies using the clearly defined IHS criteria for
the diagnosis of migraine typically estimate the lifetime prevalence of migraine to be
between 24-30% . Migraines are also associated with severe life impairment. A recent
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review identified that, on average, researchers have found that 50% of individuals with
migraine headaches miss more than one day of work a year due to headache pain, 50%
discontinue normal activities, and 30% cancel family and social activities (Stewart et al.).
Although the economic impact of a migraine headache is difficult to assess, best estimates
indicate the indirect cost of migraines in the United States to be between $1.4 billion-17.2
billion a year (de Lissovoy & Lazarus, 1994). While many of the prevalence and impact
estimates are complicated by migraine classification problems, the above estimates suggest
that migraine headaches cause serious disruption in the lives of millions of people each
year.
There are a variety of current theories that attempt to explain the pathophysiology
of migraine. Each theory is extensive and highly debated in the research literature. A full
description of each theory is beyond the scope of this paper. However , several of the most
influential theories will be briefly discussed . Historically, research on the pathophysiology
of migraine headaches has largely been driven by the theories generated by Wolff in the
1940s. Wo I.ffpurposed that migraine headaches were caused by increased pressure on
major cranial arteries. Increased pressure was hypothesized to be the result of prolonged
dilation of veins and arteries (Taylor, 1991). Dilation was suggested to be triggered by an
external event. Common events associated with the onset of a migraine have been noted to
be psychological stress, orgasm, flickering lights, certain foods (e.g., chocolate and red
wine), and sound.
New theories about pathophysiology of migraines have moved beyond WolfPs
original conception and have begun to explore the biological mechanisms involved in
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migraine and suggest that the pathophysiology of migraine is much more complicated than
previously thought. For example, central pain mechanisms have been implicated in the
production and maintenance of migraines (Raskin, 1988). Specifically, it has been
hypothesized that abnormalities may occur in the brain stem pain modulation system .
These abnormalities may cause a rapid depolarization of cerebral neurons and may occur
during or just prior to the onset of the migraine headache . Others have suggested that
individuals who experience migraine headaches have an inherited susceptibility to
headache (Lance, 1993). This susceptibility is thought to be influenced by an interaction
between exogenous and endogenous factors. Once influenced (by either an internal event
or external event) the balance between inhibitory and excitatory neurons may be altered ,
which is hypothesized to impact the serotonergic system, vascular pressure , and cranial
circulation; thereby , producing intense head pain. While most of the new research on the
mechanisms involved in migraine headache has focused in the biological arena, no
researchers have ruled out or adequately explained the influence of exogenous factors.
New theories for migraine headaches are working to identify the specific mechanisms
involved in the production and maintenance of the migraine.
In sum, the course of a migraine headache is idiosyncratic and can often be difficult
to diagnose. Symptom profiles can include intense unilateral head pain, vomiting, and
photophobia. Many individuals with migraine headaches experience an early onset of pain
(childhood or adolescence), but, a later onset in not uncommon. Five distinct phases have
been identified in the course of a migraine (prodrome, aura, headache, resolution, and
postdrome ). Migraine course is not consistent from individual to individual, thus, any or
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all of the phases may be present. The pathophysiology of the migraine headache is
considered to be highly complex and multifaceted. Current theories consider both external
(triggers) and internal events (biological mechanisms) to be important in the etiology of a
migraine headache (Capobianco et al., 1996).

Tension Headaches
In contrast to migraine headache, tension headaches are characterized by a bilateral
head pain that is nonpulsing and can last up to 7 days. Head pain in tension headaches is
usually described as dull, nagging, persistent , tight and constricting (Dalessio, 1994).
However, the most severe pain in tension headache may occur in the neck and shoulders .
Tension headaches are not accompanied by nausea, photophobia or phonophobia
(Holroyd & French , 1995). It has been commonly thought that tension headaches are the
result oflong-term contraction of cranial and neck muscles (Featherstone , 1985). In
addition to muscle contraction, some of the same central pain mechanisms that are being
investigated in migraine headaches have also been implicated in the pathophysiology of
tension headaches (Raskin, 1988). The prevalence of tension headaches is even more
difficult to estimate than prevalence of migraine. It has been suggested that the difficulty in
estimating tension headache syndromes lies in the high levels of self-treatment that occurs
(over-the-counter medication) and the high degree of overlap that is seen between tension
headache pain and other clinical syndromes (migraines, back pain, surgical pain;
Featherstone). Despite these complicating factors, it has been suggested that tension
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headaches (as defined by the IHS criteria) occur in 88% of women and 69% of men
(Rasmussen, Jensen, & Olesen, 1991).

Mixed Headaches
Mixed headache syndromes are those that consist of discrete periods of both
tension and migraine headaches. Individuals with mixed headaches may experience both
migraine and tension headaches within a 1-month period. Reliable estimates of prevalence
and impact of mixed headache syndromes are not available due to problems with diagnosis
and research methodology.
Thus, recurrent headaches are a problem for millions of people each year. The
migraine is a particularly problematic type of recurrent headache. Migraines result in
severe head pain, lost work days, and health care costs that exceed a billion dollars a year
nationally. Migraine headache syndrome is differentiated from tension headache syndrome
by the type of head pain, the associated symptoms , and the postulated pathophysiology of
the headache. When migraine headaches and tension headaches both occur in the same
person, the headache syndrome is classified as mixed type. There is a lack of
understanding of the etiologic pathways involved in the onset and maintenance of migraine
headaches and, currently, there is no permanent cure for migraine headaches. However,
there has been a variety of techniques and pharmacological agents developed that are
designed to treat migraine headache syndrome. The next section examines these
treatments.
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Types of Treatment Currently Being Used

The ambiguity surrounding the pathophysiology of migraine headache syndrome
has contnbuted to the proliferation of treatment techniques in both medical and
psychological fields. As one might suspect , medical developments have been largely
pharmacological in nature; psychological treatments have largely focused on relaxation,
biofeedback , and cognitive interventions. Pharmacological treatments are numerous and
varied, thus three major categories and the most popular treatment in each category will
be briefly reviewed. Then, nonpharmacological treatments will be summarized . The
purpose of this section is to identify major treatment categories. The results of the
previous outcome literature will be reviewed later.

Pharmacological Treatments
Pharmacological treatments for migraine headaches have evolved significantly over
the past two decades. Many narrative reviews published in the past few years attempted to
identify possible medication choices for individuals suffering from migraine headaches
(e.g., Capobianco et al., 1996; Solomon, 1995). A briefreview of available
pharmacological agents is provided here (based on Capobianco et al.; Solomon) in order
to identify the pharmacological modalities used in the treatment of migraine headaches.
Pharmacological treatments have generally been classified as prophylactic and
symptomatic treatments (Capobianco et al., 1996). Symptomatic treatments treat the pain
once the symptoms have begun (Solomon, 1995). Symptomatic treatments are commonly
used with individuals who have infrequent migraine attacks. Prophylactic treatments are
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the primary concern ofthis paper, prophylactic therapy is used with patients who have
regular migraine headaches and works to prevent the onset of the migraine. Capobianco et
al. report that a prophylactic treatment should only be considered when any of the
following criteria are met: (a) patients are taking excessive amounts or medication, (b)
they have regular headaches, (c) they have attacks that are severe and last more than 48
hours, (d) the patient is unable to cope with pain and life effects, and/or, (e) attacks occur
after a prolonged aura. When a client meets one or more of these conditions , several
classes of medications can be considered.
There are several major pharmaceutical classes of prophylactic agents. The three
major classes considered in this project are the beta-adrenergic blockers , calcium channel
blockers , and anticonvulsants. These three categories are the most commonly suggested
for use by researchers and physicians (Capobianco et al., 1996) and have the most
published work on them. Within each class a single agent was chosen for analysis in this
paper. The agent for analysis was chosen by identifying the one in each class that had the
most published research (for more details see Methods section). Through this fashion,
Propranonol (a beta-adrenergic blocker), Flunarizine (calcium channel blocker) , and
Divalproex Sodium (anticonvulsant) were chosen as the primary targets. Each of the
agents have brand names, generic names and chemical names (see Appendix A for list of
agent names). For the purposes of this paper the generic names will be used to avoid
confusion. A brief review of the properties of each agent follows.

Propranonol. Propranonol, also known as Propranolol Hydrochloride, has been
used for migraine prophylaxis for over 30 years. Early reports indicate that practitioners
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observed that patients receiving Propranonol for cardiovascular disorders also displayed a
decrease in co-existing migraines (e.g ., Rabkin, Stables, Levin, & Suzman, 1966). These
observations led to a proliferation ofresearch studies on the use of Propranonol for
migraine prophylaxis.
Propranonol is known to have a beta-adrenergic blocking effect that is associated
with reduced heart rate and blood pressure (Cortelli et al., 1985). It has been suggested
that this beta-adrenergic blocking interferes with peripheral vasodilator receptors , thereby
restricting the vasodilation phase of a headache (Cortelli et al.). It has also been sugge sted
that Propranonol reduces brain wave activity, thus "quieting" the brain response
(Schellenberg, Milch, Schwarz , & Schoberg, 1994). However, not all beta-adrenergic
blockers are effective as migraine prophylaxes . Therefore , the mechanisms that account
for Propranonol ' s effects are still largely unknown (Gerber et al., 1995) . .
Caroll, Reidy, Savundra , Cleave, and McAish (1990) reported that Propranonol
has a short half-life ranging from 2-4 hours in its conventional preparation. They go on to
state that a long acting formula is available which has a half life of 10-20 hours .
Recommended dosages for migraine prophylaxis range from 40-240 mg. Side effects
include tiredness , reduced heart rate , reduction of blood pressure, and dizziness (Caroll
et al.).
Flunarizine. Flunarizine as a migraine prophylactic has a unique history. Most
other migraine prophylactic drugs have been extended to migraine patients after an effect
was noted while treating another condition. Flunarizine does not follow this historical
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course. Flunarizine is one of the few agents purposed through the scientific method to be
an effective prophylactic agent for migraine.
Flunarizine was suggested to be a migraine prophylactic by a group of pharmacists
(Amery, 1983) after studying the biopathophysiology of migraine. The Amery group
hypothesized that a period of brain hypoxia was the critical event in migraine genesis.
Cerebral hypoxia has been associated with the flooding of calcium ions in cerebral arteries
(Amery). It has been suggested that cerebral arteries are unique in that they require
external calcium ions to contract (as opposed to other vasculature that use intracellular
calcium stores to contract). According to the Amery theory, only a drug that decreased
the potential for brain hypoxia would be an effective prophylactic agent. Thus , they
proposed Flunarizine (a unique calcium channel agonist) would be the most ideal agent
available. Flunarizine is a difluorated piperazine derivative that inhibits the influx of
calcium ion into vascular smooth muscle cells (Louis , 1981 ). Thus , the use of Flunarizine
may inhibit the influx of the intercellular calcium ion, thereby reducing the likelihood that
the cerebral arteries can begin the contraction series seen in migraine (Steardo et al.,
1986).
Diamond and Schenbaum (1983) suggested that Flunarizine has another property
that contributes to its success as a migraine prophylactic agent. Research indicates that
Flunarizine works to block Hl histamine receptors while simultaneously inhibiting
vasoconstriction and serotonin activity (Diamond & Schenbaum). Histamine and serotonin
have been shown to be present in the brain in high amounts during migraine activity
(Steardo et al., 1986).
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Flunarizine has a long half-life (duration of action is approximately 24 hours),
which results in a delay in treatment effect (Mendopoulous, Manafi, Logothetis, &
Bostantzopoulou, 1985). Initial effects are noted between 30 and 90 days (Louis, 1981).
Recommended doses for migraine prophylaxis range between 5-1 Omg. High doses of
Flunarizine (more than 30 mg) over long periods of time have been associated with
reversible Parkinson-like side effects (Schmidt & Oestreich, 1991). More common side
effects include: daytime sedation (Steardo et al., 1986), weight gain (Amery, 1982),
depression (Schmidt & Oestreich), dry mouth and skin rash (Martinez-Lage, 1988).
Flunarizine is not currently approved by the FDA for use with migraine patients in
the United States. The reason for this is unknown. The researcher contacted the FDA
regarding Flunarizine and they responded by stating that it is illegal for them to disclose
information about an agent under law 21 CFR 314.430. They stated that all information
belongs to the manufacturer of the agent. Thus, I contacted Janssen-Cilag on four
occasions to try to get information regarding Flunarizine's drug status in the United
States. No response was ever received. Janssen-Cilag is a subsidiary of Johnson and
Johnson. Johnson and Johnson moved many of its production plants to Canada and
Belgium in the early 1990s. This would have been around the same time the Flunarizine
would have become a candidate for FDA review. Even without FDA approval, Flunarizine
is one of the most commonly used and researched prophylactic agent in countries outside
of the United States.

Divalproex Sodium. This treatment is composed of one part sodium valproate and
one part valproic acid (Mathew, 2001). Divalproex Sodium dissociates in the

16
gastrointestinal tract to valproate. Valproate is hypothesized to increase the levels of
gamma-aminobutyric acid (GABA) in the brain (Mathew). It is thought that the increase in
GABA levels in the brain serve to reduce the "hyper-excitability" of the brain that is
thought to be associated with migraine (Shelton & Connelly, 1996). That is, it is believed
that the brains of individuals with migraines are susceptible to a variety of stressors (both
physical changes and outside stressors) . This is believed to cause the brain to be
hyperexcitable and cause a vasoconstriction reaction that will start a migraine.
Divalproex Sodium is also thought to have additional properties that aide in
migraine prophylaxis . It is suggested that Divalproex Sodium may inhibit the release of
prolactin (Jensen, Brink, & Olesen, 1994). Prolactin is thought to be released in high levels
during an ischemia (Shelton & Connelly, 1996). Thus , it is thought that Divalproex
Sodium may offer some protection against migraine during the aural phase.
Divalproex Sodium has been used for epilepsy, infantile spasm, photosensitive
epilepsy, and migraine (Silberstein & Wilmore, 1966). The FDA has approved Divalproex
sodium for use as a migraine prophylaxis. The plasma half life ofDivalproex Sodium is 817 hours (Silberstien & Wilmore). Recommended doses for migraine prophylaxis are 4002500 mg a day and migraine reduction is likely to be seen in 30 days (Landy & McGinnis,
1999). Most of the agent is metabolized in the liver, which can result in liver damage if
appropriate levels are exceeded (Shelton & Connelly, 1996). Documented side effects can
include tremor, weight gain, alopecia (Thomas, 1989), gastrointestinal disorders, and
gastroesophageal reflux disease (GERD; Landy & McGinnis);
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Nonpharmacological Treatments
A variety of nonphannacological treatments have been developed to treat migraine
headache syndrome . These treatments are based on the theory that controllable responses
like stress , tension, heart rate, blood pressure, and negative cognitions contribute to the
development, maintenance, and interpretation of the recurrent migraine. The most
commonly researched nonphannacological treatments are briefly reviewed here. It is noted
that each treatment described is rooted in a theoretical orientation, has extensive treatment
procedures, and has many treatment variations . However, a full discussion of all of these
issues is beyond the scope of this paper.

Biofeedback treatments . In a recent nonquantitative review of supported
psychological treatments for migraines , Holroyd and French (1995) report that thermal
biofeedback plus relaxation training and EMG biofeedback plus relaxation training are two
of the most widely used nonpharmacological treatments for migraine headaches.
Biofeedback is a method of achieving control over bodily processes that are usually
outside of the client's awareness. Biofeedback targets a function (hand warming in thermal
feedback and muscle tension in EMG biofeedback) and provides continuous feedback
(typically visual and/or auditory) regarding the target function to the client (Taylor, 1991).
With continuous feedback, typically provided via a computer, and through trial and error,
clients learn to gain control over their target functions. After successful training clients are
theoretically able to control their target function without the use of the mechanical
feedback (Blanchard, 1994).
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Relaxation treatments. Relaxation training is also used to treat clients who suffer
from migraine headaches. Relaxation training guides the client to move toward a less
physiologically aroused state (Taylor, 1991 ). Procedures for relaxation training may use
any combination of deep breathing techniques , muscle relaxation, and imagery (Malone &
Strube, 1988). Treatments typically involve five to eight sessions and include some form
of daily home practices. Clients may be given workbooks or audiotapes to aide in their
practice at home. In some cases , relaxation techniques have been used as the sole
treatment or in combination with biofeedback.

Cognitive treatments. Another commonly reported treatment for migraine
headache sufferers is cognitive or cognitive-behavioral therapy. Cognitive treatments are
aimed at helping clients alter their perception of pain. In cognitive treatments , clients meet
with a therapist and learn to monitor the thoughts , feelings, and behaviors that enhance
their sensation of pain (Holroyd & French , 1995) . Clients then learn to alter their behavior
and thinking to patterns that are associated with less pain. Common protocols for migraine
prophylaxis that use cognitive training use components of rational emotive therapy and
coping skills training.

Summary

In summation, none of the above described treatments are considered to be a
"cure" for migraine headaches. Rather, both the pharmacological and nonpharmacological
treatments seek to reduce the duration , intensity, and frequency of pain in clients
(Solomon, 1995). Between the pharmacological and nonpharmacological categories there
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are over 30 different treatment options. Treatment choices become even more confusing
when turning to research for guidance. A simple perusal ofMEDLINE and PSYCHINFO
databases reveals that each treatment option has many (from 2 to 12) primary studies
touting its "effectiveness." It is apparent in the above description of available treatments
that the abundance of choices can be overwhehning for professionals and consumers. The
data regarding the effectiveness of all the treatments for migraine headaches needs to be
quantitatively analyzed so that treatments can be compared to one another. A metaanalysis is a good vehicle for this kind of analysis of multiple primary studies (Carroll,
1996). Thus, a comprehensive meta-analysis was undertaken to evaluate the effectiveness
rates of six empirically supported pharmacological and nonpharmacological treatments for
migraine headache syndrome.

Suggested Evidence for Evaluating the Effects
of Treatments

It is important to have a common understanding of the meaning of a "potent

treatment" before attempting to compare the effects of various treatments. Guidelines
have recently been proposed for defining efficacious and effective treatments. Chambless
and Hollon (1998) detailed minimum research requirements for an efficacious treatment.
First, they stated:
Treatment efficacy must be demonstrated in controlled research in
which it is reasonable to conclude that benefits observed are due to the
effects of the treatment and not to chance or confounding factors such
as passage of time, the effects of psychological assessment or the
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presence of different types of clients in the various treatment conditions .
(p. 7)
The authors also recommend that at least two controlled studies, conducted by
independent researchers, need to be conducted for a specified condition. This is a
particularly salient issue for many of the pharmacological treatments of migraine
headaches. Many medications are recommended for use with migraine headache sufferers,
yet lack controlled studies to support their use for this specific purpose.
Chambless and Hollon (1998) described some designs that should be given more
weight when attempting to evaluate the efficacy of a treatment. Randomized trials are
considered to be the "gold standard" for treatment evaluation and constitute the best
evidence. In addition, treatment evaluation should be considered hierarchal in nature.
Results that come from treatment studies with no comparison groups should be held more
tentatively than results from studies comparing treatment to a control, placebo, or no
treatment group. Better yet are results from studies that compare effects of a new
treatment to the effects of another established treatment. According to Chambless and
Hollon, this is the premier type of efficacy research. Comparison studies that examine the
treatment effects of two or more treatments can result in explicit information regarding
relative benefits of the two treatments. Unfortunately, in the area of migraine headache
there are only a few primary studies that compare the treatments to each other. Those that
do compare treatments typically compare them within the same category (e.g., EMG
biofeedback to thermal biofeedback or Propranonol with Flunarizine ). Primary studies that
compare treatments between groups are very rare. It has been suggested that this may
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occur because medical and nonrnedical professionals become so exclusively focused on
their treatment modalities that research collaboration seldom occurs (Holroyd & Penzien,
1990). However, the lack of primary research comparing the numerous treatment
modalities available for treating migraine headaches does not abate the need for
professionals and clients to be able to evaluate the relative effects of the treatments.
One possible solution to this problem is a large-scale evaluation project. Such a
project could compare each available treatment option for migraine headaches, tension
headaches , and mixed headaches in a controlled evaluation. However , the number of
needed subjects to do a primary research study comparing the success or improvement
rates of treatments for migraine headaches would be enormous. Chambless and Hollon
(1998) recommended that a minimum of 50 subjects per condition should be used in
efficacious research. If this guideline were adhered to , a research study examining
outcome of the most common treatments for migraine headaches would require
approximately 1700 subjects. Even more subjects would be needed if each treatment
group were to be matched with a control group. The project would require collaboration
between many groups and professionals and would be costly to conduct. However, the
information provided in such a study would be invaluable. Even if this type of large scale
study were conducted, replication would be needed before confidence could be gained in
the results.

In the absence of such large scale projects another alternative is available. The use
of meta-analytic techniques as suggested by Glass (1976) allows for the quantitative
analysis of a large number of primary analysis results for the purpose of integrating and
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comparing these results. A meta-analytic review comparing all methods of treatments for
migraine headaches would provide a way for previously obtained results in each individual
area to be compared and evaluated.

Previous Reviews

In preparing to conduct a meta-analytic review, it is appropriate to evaluate
previously conducted reviews on related topics (Glass, 1976). This allows the new metaanalytic review to benefit from previously obtained data and avoid pitfalls that others may
have encountered. The area of treatment efficacy research for migraine headaches is
marked by several well-conducted quantitative reviews and many insightful narrative
reviews. Reviews were identified by using combinations of the key words "review,"
"effective," ''treatment ," "migraine," "pain," "outcome," and "headaches" in both the
MEDLINE and PSYCHINFO databases (1970 to 7/2003) . This search strategy identified
102 reviews. Of these, 19 were in a foreign language and 36 presented only information of
the pathophysiology or diagnosis of headaches. In addition, a substantial number (N = 32)
of pharmacological reviews were eliminated because they did not meet selection criteria.
For example, many reviews in pharmacological literature present only an author's personal
experience with, or opinion of, a treatment for migraine headaches. These reviews do not
evaluate controlled studies and provide little information about the effectiveness of the
treatments. Thus, the reviews presented here (N= 12) met the following criteria: (a) the
review provided information regarding the effectiveness of a recurrent headache
treatment(s) in either narrative or quantitative form, (b) if the review was narrative then it
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must review empirically conducted research, and (c) the review was written or translated
into English.
The reviews presented here are evaluated by quality of research design based on
six criteria: (a) selecting and delimiting the topic, (b) review of previous reviews in
relevant areas, (c) selecting an appropriate sample of studies, ( d) data collection
procedures, (e) analyzing results, and (t) interpreting and reporting results. Based on these
criteria, each review was given an excellent, good, or poor rating. Recommendations
based on the literature will be followed by a brief critique of the available reviews in each
area.
This paper's examination of previous reviews is broken up into five separate
sections. The first examines those reviews which attempt to compare effectiveness rates of
treatment(s) from the pharmacological category with treatment(s) from a
nonpharmacological

category. Again, according to Chambless and Hollon (1998), this

type of comparative information is considered to be the "best evidence," thus, these
reviews are considered first and in some detail. Then, reviews that considered just
pharmacological treatments for headaches are examined, followed by reviews that
considered only nonpharmacological

treatments. Then, other relevant reviews that

provided valuable information about potential correlating variables will be briefly
examined. Finally, a recent work that critiques meta-analyses in general will be discussed.
A brief summary of major findings and considerations of each existing review can be found
in Appendix B.
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Reviews Comparing Pharmacological and
Nonpharmacological Treatments

There are only two existing reviews that integrate pharmacological and
nonpharmacological treatments for recurrent headaches in adults. One of these reviews
focused solely on treatments for migraine headaches, the other focuses on tension
headaches. The first of these reviews compared the effectiveness of a biofeedback/
relaxation combination treatment to medical administrations of Propranonol in adult
migraines. The second review focuses on both pharmacological and nonpharmacological
treatments for tension headaches in adults. These meta-analytic reviews are of varying
quality, but all provide valuable insight into treatment outcome in recurrent headaches.

Holroyd and Penzien
The first meta-analytic review is an excellent evaluation of the treatments for adult
migraine headaches. This review compared the treatment effects of Propranonol and
relaxation/biofeedback training. Holroyd and Penzien (1990) used meta-analytic
procedures to examine results of primary research studies conducted up to 1989 in
migraine suffers (although some mixed headache suffers were included). Four conditions
were compared in this review: Propranonol, biofeedback/relaxation, placebo, and no
treatment conditions.
Change was variably calculated in the Holroyd and Penzien (1990) review. First, if
the primary research articles reported a headache index score, this was used as the change
index (the headache index is a composite score that weights and combines intensity and
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duration of headaches). However, an undetermined number of studies did not report
enough data to calculate the headache index score; therefore, for some studies the authors
calculated a "composite headache index score." This score was calculated from an average
ofreported scores (any or all of frequency, duration, and intensity change scores). Authors
reported a significant correlation (r

=

0.86) between the two methods of calculating

change (headache index and their composite headache index score).
Holroyd and Penzien (1990) coded for method of estimating change improvement
scores. Some of their primary studies used daily recording journals , where others had
practitioners make end-of-treatment gain estimates. The authors found that results differed
by approximately 20% if daily headache measures were used to calculate change. That is,
the reported improvement in headache activity was 20% lower in studies that had
participants rate their headache daily rather than having a therapist or physician rate the
change. This difference was significant (p < 0.001). Calculations examining only the data
from the studies employing the daily recording of headache activity revealed 43.3 % mean
improvement in headache in both the Propranonol and the relaxation/biofeedback
conditions. Both Propranonol and biofeedback/relaxation showed significantly (p < 0.001)
higher treatment effects than the placebo and untreated conditions.
These authors based their results on two different types of change scores. In some
studies the change score (the headache index) was taken directly from the primary report .
In other cases the authors averaged across three variables (duration, frequency, and
intensity). The headache index does not account for frequency thus the two methods of
computation may have led to dramatically different results. In addition, this review
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examined only one type of prophylactic treatment, Propranonol, and excluded the others.
Propranonol is the most frequently prescribed prophylactic pharmacological treatment,
however, this does not indicate that Propranonol is the most efficacious treatment or the
only one worthy of study. Also, Holroyd and Penzien examined only studies through
1989. Over 40 new studies have been published on treatments for migraines in the last 9
years. These additional studies could render some of the Holroyd and Penzien's
conclusions outdated. Finally, it is noted that the authors make a particularly important
recommendation for future research. They note that while effectiveness rates are
compared at the end of treatments it is unclear what long term effects, if any, these
treatments have.

Technical Review Conducted by Duke University
and the Center for Clinical Health and
Policy Research

The second review is a two-part review developed in part for the Agency for
Health Care Policy and Research. This study has not been published (likely due to length
and complexity) outside of the NTIS Website. The review was posted (at NTIS) after the
proposal date of the current project and it mirrors many of the current author's intentions.
The first part of the part of this review (authored by Duke University and The Center for
Clinical Health Policy and Research, 1999a) synthesizes the data for behavioral and
physical treatments for migraine. The second part (Duke University and The Center for
Clinical Health Policy and Research, 1999b) synthesizes the data for prophylactic
pharmacological agents for migraine. This methodologically sophisticated review is
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excellent in most aspects. The review only included randomized controlled trials of
pharmacological , psychological , behavioral and physical (e.g. , acupuncture) treatments. A
comprehensive group of findings are presented that include more than the six treatments
evaluated by the current meta-analyses. Findings from this excellent quantitative review
indicated that most pharmacological and nonpharrnacological treatments had functionally
equivalent effect sizes (all of which were in the moderate range). A similar pattern and
magnitude of findings was reported for nonpharmacological treatments.
Standardized mean difference effect sizes for nonpharrnacological treatments
ranged from .08-1.61. The nonpharrnacological treatments and summary weighted mean
effect sizes are as follows: relaxation (es= .55), thermal biofeedback (es= .38), thermal
biofeedback plus relaxation (es = .40), E.G. biofeedback (es = .77), cognitive behavioral
therapy (es = .54), and thermal biofeedback plus cognitive therapy (es - .37). The
pharmacological meta-analysis examined 52 treatments that included hormonal treatments
for menstrual migraine. They report that the top seven agents with their effect sizes are
naproxen sodium (es= .62), Flunarizine (es = .52), Propranolol (es= .55), amitriptyline

(es= .62), Timolol (es= .69), pizotifen (es = .91), Divalproex Sodium (es= .93). The
other pharmacological agents examined in this study were reported to have variable results
with low effect sizes.
However, this meta-analysis does not compare the findings between the two
groups. Instead they report their findings in two separate reports in two separate formats.
Of additional interest was the authors' choice in this review to use varied statistical
procedures for pharmacological studies and nonpharrnacological studies. Standardized
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mean difference scores and odds ratios are calculated for pharmacological studies, non
pharmacological studies include standardized mean differences and percent improvement
measures. This is curious given the emphasis on consistency of evaluation methods across
domains. The percent improvement scores were used in the Duke study as a cross check
for standardized mean difference scores. The authors reported that the percent
improvement scores in some cases underestimated treatment effects. In addition, percent
improvement scores have been criticized because this procedure averaged unstandardized
data and can be misleading.

Summary of Reviews That Compare Pharmacological
and Nonpharmacological Treatments
A total of two reviews exist that evaluate pharmacological and
nonpharmacological treatments for recurrent headaches. An evaluation of the these
reviews indicates that: (a) Propanonol, relaxation training , biofeedback , and cognitive
therapies all have been reported to produce similar treatment outcomes and improvements
in migraine sufferers (both adults and children); (b) percent improvement scores may
underestimate treatment effect; and (c) type of outcome measure highly influences the
results of the study.
Cumulatively, the reviews identify several pitfalls for future researchers. First,
change scores should be calculated for frequency, intensity, and duration if headache
scores are not available. If standard deviations are presented in primary literature,
standardized effect sizes should be calculated. Next, it may be wise to use all available
studies and code for quality rather than eliminate studies due to methodological flaws.

29
Finally, when examining both pharmacological and nonpharrnacological studies
researchers should report specific treatment effects, in addition to categorical effects (i.e.,
pharmacological or nonpharrnacological).

Pharmacological Reviews

This section examines those reviews that focus on pharmacological treatments.
Two quantitative reviews on migraine headaches exist in this area. (Holroyd, Penzien, &
Cordingley, 1991; Onghena & Van Houdenhove , 1992). Other narrative reviews are
available (e.g., Capobianco et al., 1996; Solomon, 1995), however, the reviews are
primarily informational in nature and focus on side effects of the medications and
contraindications. This section will focus only on those reviews that are quantitative in
nature.

Holroyd, Penzien, and Cordingley
The Holroyd et al. (1991) review examines existing literature on the effectiveness
of Propranonol as a prophylactic treatment for recurrent migraines. This review
synthesized data from 53 studies, which resulted in a total of 73 groups (Propranonol and
placebo). The Holroyd et al. review calculated two different types of change scores. The
first was pre-post treatment gains, the second subtracted gains of the placebo groups from
the gains of the treatment (Propranonol) groups. Change scores were analyzed separately
and results varied significantly by method of calculation. That is, change scores were
lower when placebo groups were used in the calculation instead of pretreatment scores.
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The Holroyd et al. review concludes, that on, average prophylactic use of Propranonol
results in a 44% reduction in migraine activity when the most conservative outcome
measures are used (patient daily diaries) and when change is compared to placebo groups.
Estimates are higher when less conservative measures are used (clinician ratings of preand posttreatment scores).
This review is considered to be excellent because it has clear selection criteria and
identifies correlates of treatment outcome (age, gender, mortality, mortality due to sidee:ffects, dose of active agent , chronicity of headach e, and quality of study). While
providing excellent information about the use of Propranonol , the net result is information
that is difficult to interpret. This is because Propranonol is compared only to placebo
groups and not other treatments. Thus, it is difficult to identify whether Propranonol is
better, equal to , or worse than other prophylactic treatments. The authors of this review
report that Propranonol has equal effectiveness rates to other phannacological
prophylactic treatments, but no data are provided to support this position.

Onghena and Van Houdenhove
Onghena and Van Houdenhove (1992) conducted a good meta-analytic review of
antidepressant-induced analgesia in chronic pain patients. Thirty-nine placebo controlled
studies were examined; 10 were conducted with migraine, tension headache, or mixed
headache subjects. This review provides an adequate description of selection procedures,
the problems with primary research validity, quality of study, compliance, and types of
medication used. Conclusions indicate that patients with migraines, tension headaches, and
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mixed headaches showed statistically significant improvements in their headache activity
when using an antidepressant medication. In addition, larger effect sizes were noted for
recurrent headache patients than any other pain category .
Yet, the findings in the Onghena and Van Houdenhove (1992) review are difficult
to interpret because they do not compare the analgesic effects of antidepressants to
analgesic effects of any other pharmaceutical agent. The results of this meta-analysis are
important , but difficult to integrate with other analgesic findings. However , this review is
one of the few that quantitatively evaluate pharmacological treatments , thus providing
important design information. In this study it was recorded whether other drugs were
allowed to be taken during the study, the activating profile of the drug (psychomotor
activation, nonactivating/nonsedating , and sedating) , in-patient status, mean age, duration
of pain, side effect profiles of the drugs, numbers of subjects dropping out due to side
effects, and patient profiles indicating drug selection.
The last point is of particular interest. Many of the pharmacological interventions
have a highly selective process to determine if subjects can safely take the medication.
Selection processes may include the consideration of pre-existing medical conditions, age,
previous response to medications, current medications taken, and side effect profiles of the
pharmacological agent (Solomon, 1995). This selection process may introduce a selection
bias that is not comparably matched in the nonpharmacological research that may cause
problems in the comparison of the two interventions. To best attempt to compare the
pharmacological and nonpharmacological treatments the above information should be
gathered on all primary studies (pharmacological and nonpharmacological).
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Summary of Pharmacological Reviews
Both of these reviews offer insight into procedures that are helpful when reviewing
pharmacological literature. For example, Holroyd et al. (1991) suggested that change
scores should be calculated in two forms and then results should be analyzed separately.
The Onghena and Van Houdenhove (1992) review suggests that reviews of
pharmacological research should examine several variables. These include; identification of
other medications taken (analgesic and others), inpatient status, age, and duration of pain.
In addition, both reviews (Holroyd et al.; Onghena & Van Houdenhove) indicated that
overall mortality rates versus mortality rates due to medication side effects should be
coded separately.

Nonpharmacological Reviews

One review that examines adult migraine headache treatment is available in the
nonpharmacological area. Compas, Haaga, Keefe, Leitenberg, and Williams (1998)
examine the outcome of biofeedback, relaxation, and cognitive treatments. Unlike the
pharmacological reviews, this review makes comparisons between treatments that provide
valuable insight into the effectiveness of treatments in relation to one another.
In narrative form, Compas et al. ( 1998) reviewed all empirically supported
nonpharmacological treatments for smoking, cancer, chronic pain, and bulimia nervosa. A
subsection is included on migraine headaches that reviews thermal and E.G. biofeedback,
relaxation, cognitive therapy, and cognitive behavioral therapy. Most of the information in
this narrative review is based on previously mentioned quantitative reviews. The authors
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report that many of the previously conducted meta-analyses have been supported by more
recent work. Nevertheless, there was no attempt to quantitatively review the more recent
work. Furthermore, Compas et al. evaluated the effectiveness of cognitive and cognitivebehavioral treatments (both of which are treatments that have not been adequately
quantitatively reviewed) and concluded that cognitive treatments are not effective in
reducing migraine headache activity.
The Compas et al. ( 1998) review was written simultaneously with the Chambless
and Hollon (1998) recommendations for evaluating empirically supported treatments. As
such, Compas et al. clearly identify studies that are randomized , provide correlational
evidence, and compare to other treatments . The list of studies generated by Compas et. al,
while not inclusive, would be essential to include in a future meta-analysis.

Other Relevant Reviews

Four other reviews will be briefly discussed. They are not specifically focused on
the treatment of migraine headaches, but they provide valuable information about potential
correlates and coding procedures. Because these reviews are less directly related to the
current topic , they will only be discussed briefly.

Flor, Fydrich, and Turk (1992)
This is an excellent meta-analytic review which investigated the efficacy of
multidisciplinary pain clinics. The authors investigated age, marital status, education level,
socioeconomic status (SES), employment status, compensation, litigation, and medication
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use. However, none of the above were found to correlate significantly with study
outcome. Though the Flor et al. study focused primarily on the treatment of back pain
patients in pain clinics, the noted correlates may be important when evaluating migraine
headaches.

Lander
Lander ( 1990) also provided a narrative review on pain management. While not
specifically addressing migraine headaches , Lander highlights the importance of client and
researcher variables in evaluating pain management techniques . Variables considered to be
important are: (a) practitioner inference about treatment gains "polluting " the outcome
measures , (b) potential differences in convenient , solicited , clinical, and nonclinical
populations , (c) gender , SES, and age as mediating variables, and (d) duration of pain.

Holroyd and Penzien
In 1986, Holroyd and Penzien conducted a meta-analysis that examined both

client variables and treatment variables that may impact the treatment of tension headache.
This review focused solely on tension headaches and nonpharmacological interventions.
Type of treatment, length of treatment, training of therapist, and attention to transfer
training did not significantly correlate with treatment outcome. However, sample
characteristics were found to significantly correlate with the reported reduction in
headache activity. Most dramatically, treatment outcome varied by age, gender, and
solicited, rather than referred clients. Primary studies with younger mean ages, more
females, and solicited samples all reported stronger treatment effects.
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Malone and Strube
In contrast to Holroyd and Penzein (1985), Malone and Strube (1988) found that
sample characteristics were not correlated with outcome of psychological treatments.
Malone and Strube conducted a meta-analysis of effective nonpharmacological treatments.
However, Malone and Strube collapsed across types of pain treatment (e.g., headache,
backache , cancer) . In addition, Malone and Strube calculated change scores for primary
studies that did not report pretesting by estimating from studies that did have similar
pretests. This procedure is based on questionable assumptions and is likely to mask true
differences. Given the procedural errors, the Malone and Strube meta-analysis was given a
poor quality rating and thus, the evidence presented in the Malone and Strube review is
not convincing.

Reviews of Meta -Analytic Reviews

Finally, one excellent quantitative review has been conducted using previous metaanalytic reviews that have examined analgesic interventions (Jadad & McQuay, 1996). The
article is primarily focused on identifying weaknesses in the current reviews and making
recommendations for reducing bias and improving quality. Jadad and McQuay report that
a simple MED LINE search missed nearly 50% of relevant articles making many of the
medically based meta-analyses incomplete. In addition, the importance of completely
identifying the methods used to locate primary studies and describing criteria for assessing
validity of primary studies was highlighted. While these recommendations are standard for
conducting a meta-analysis, Jadad and McQuay report that 26% of meta-analyses
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reviewed did not identify the selection methods, and 21 % did not identify design
characteristics of their sample.
Other important issues in meta-analysis research identified by Jadad and McQuay
(1996) are the quality and validity of the primary study. As mentioned above, many
authors have reported that quality of primary study is an important outcome variable (e.g.,
Blanchard, Andrasik, Ahles, Teders , & O'Keefe , 1980; Bogaards & ter Juile, 1994;
Holroyd & Penzien, 1985; Onghena & Van Houdenhove, 1992). Authors of metaanalyses often evaluate the quality and validity of primary studies because it has been
hypothesized that primary studies of poor design with threats to validity may produce
higher effect sizes than studies of good quality (Slavin, 1984). Therefore , the conclusions
of a meta-analysis may be overestimates if the author does not account for the quality of
the primary studies it includes. Jadad and McQuay reported that while many authors
report that they evaluated quality of study, 60% of meta-analyses did not describe
methods of assessing primary study validity and quality. Jadad and McQuay reported that
a good meta-analysis includes a systematic and objective method of assessing quality and
validity of primary studies that is specifically described in the text.
In summation, there are 12 applicable reviews in this area. Only a few of these
reviews have compared treatments to each other. Two compared treatments across
categories (nonpharmacological and pharmacological), but only one of these reviews
(Holroyd & Penzien, 1990) focused directly on migraine. The Holroyd and Penzien review
did not comprehensively examine multiple pharmacological and nonpharmacological
agents. A review of multiple pharmacological and nonpharmacological treatments is
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available for tension-type headaches (Bogaards & ter Kuile, 1994), but none exist in the
migraine literature. The remaining reviews studied the outcome of treatments within a
single category (i.e., relaxation and biofeedback in the nonpharmacological category). The
pharmacological reviews did not compare treatments at all, instead , they compared
treatments only to placebo or control groups. The net result of these reviews is a wealth of
information that is almost as difficult to interpret and use as the individual primary studies.

Summary

Migraine headaches are a disabling problem for millions of Americans . There are
over 30 treatments available for migraine headaches. Much of the primary research in the
area of migraine headaches is focused on identifying the effectiveness rates of these
treatments in comparison to control or placebo groups. This procedure does not allow for
the comparison between treatments. Only seven primary studies have conducted research
that compares a pharmacological and nonpharmacological intervention. As a result, there
is a wealth of data on individual treatments that is difficult to compare to one another and
use (Chambless & Hollon, 1998). A synthesis is needed to make the data more
manageable. There have been a variety of systematic reviews conducted in this area,
however, their focus is too narrow and some are now outdated. Therefore, a more
comprehensive meta-analysis that includes an evaluation of both pharmacological and
nonpharmacological treatments on migraine headaches needs to be conducted.
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CHAPTER III
PURPOSE OF STUDY AND RESEARCH QUESTIONS

The purpose of this study was to integrate data available on pharmacological and
nonpharmacological treatments for migraine and mixed headaches. Mixed headaches were
being included because of the high overlap between the two syndromes. This study is a
meta-analysis and, thus , will quantitatively compare effectiveness rates of many different
treatments .
1. How do the effectiveness rates of treatments compare to each other and
between groups (pharmacological and nonpharmacological)?
· 2. What sample characteristics are significantly correlated with outcomes? Do
these characteristics vary by treatment category?
3. Do outcomes vary if broken into two levels of empirical evidence (placebo
control group comparison, and multiple treatment comparison) as suggested by Chambless
and Hollon (1988)?
4. What information is available regarding short and long term effectiveness rates
for pharmacological and nonpharmacological studies?
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CHAPTER IV
METHODS

The methods used in this meta-analysis are described below. First, procedures for
selecting the treatments and primary articles to be evaluated are discussed. Then, a
description of the sample with a list of articles included in the meta-analysis is provided.
Data collection and quality rating methods are discussed next. Finally, methods and
rationales for analysis are presented.

Selection of Sample

The selection of studies to be included in the current meta-analysis followed a
multistep procedure. First, popular classes of treatment were identified, then the most
frequently researched treatments within the class were identified. Once identified, all
outcome studies regarding the treatments were gathered. A search strategy was developed
to ensure comprehensiveness. Once primary articles were obtained, inclusion and
exclusion rules were applied. Each of these steps are described in turn below.
The current meta-analysis identified six different treatments for migraine
prophylaxis to compare. Treatments to be evaluated were selected by conducting a
preliminary literature search of available classes of treatments. In the pharmacological
treatment area a preliminary literature search identified three major pharmacologic classes
that are currently being researched for use as prophylactic agents: beta-blockers, calcium
agonists, and anticonvulsants. Once these classes of medications were identified, a more

40
comprehensive abstract search identified which pharmacological agent had the greatest
number of controlled published research outcome studies. This process identified the top
three agents in each category; Propranonol , Flunarizine, and Divalproex Sodium. This
process was duplicated for nonpharmacological prophylactic treatments for migraine. The
preliminary literature search in the area of nonpharmacological treatments identified
thermal biofeedback, relaxation therapies, and mixed therapy treatments as the most
researched areas.
Once the treatments for inclusion in the meta-analysis had been identified, a more
comprehensive literature search began. A search for published , peer-reviewed literature on
the effectiveness of each treatment was conducted. Literature published between 1970 to
July, 2003 was included in the search. This search included searches ofMEDLINE,
PSYCHINFO , ERJC, and the Current Contents databases. Key words used in database
searches included combinations of the following: the treatment names, controlled , random ,
effectiveness , prophylaxis, migraine, headache, vascular headache , treatment , and
outcome. In addition, reference sections of reviews on these treatments were checked and
cross-referenced to ensure comprehensiveness. Finally, the last year (2002-2003) of Pain,

Headache, Journal of Consulting and Clinical Psychology, Journal of the American
Medical Association, & Cephalalgia were reviewed for newly published articles that may
have not been accounted for in the computer-based search.
After articles had been identified in the above-mentioned treatment categories, a
set of inclusionary and exclusionary rules were applied to each article. Inclusion rules
included (a) three studies examining a single treatment for migraine headaches must exist
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for a treatment to be considered in the meta-analysis, (b) studies had to have at least five
subjects in each condition to be considered in the meta-analysis, (c) study evaluated a
pharmacological or nonpharmacological treatment for migraine or mixed headache, and
( d) study must provide enough numerical detail to calculate at least one change score per
condition. Studies were excluded from the analysis if (a) the study did not compare the
treatment to a placebo, control group or comparison treatment,(b) the study was
conducted with animals, ( c) the study only examined children under the age of 18, ( d) the
study was published in a foreign language, (e) the study reported on the same data that
had already been reported elsewhere, (f) the study employed a single-subject research
design, and (g) the study was an analogue study.

Description of Sample

Approximately 400 articles were obtained and cataloged via a database system.
This number includes approximately 200 articles that were eliminated because they
evaluated the wrong treatments, were reviews, did not provide original data, provided
practitioner guidelines only, or had a focus other than treatment outcome evaluation. The
selection criteria were then applied to the 191 remaining articles. Careful documentation
was kept on each article that was excluded. This process resulted in examination of 57
articles in the Propranonol category and the retention of 30 articles, 52 articles in the
Flunarizine category and the retention of 17 articles, and 18 articles in the Divalproic
Sodium category and the retention of seven articles. In the nonpharmacological area many
of the primary studies were multi-arm studies that provided information on more than one
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treatment being included in the analysis. Thus, the sample is best described as a sample of
64 articles from which 15 studies were used to calculate 18 effect sizes in the thermal
biofeedback category. Four articles were retained in the relaxation therapy category. Nine
articles were used in the mixed therapy category (five EMG biofeedback articles and four
thermal biofeedback plus relaxation plus cognitive therapy). This resulted in 82 studies
being retained overall and included in the study, and 109 studies being excluded.
It should be noted that a large number of nonpharmacological studies were

excluded due to insufficient reporting of data in the write up. Many studies in the
nonpharmacological area were well-designed controlled studies. Interestingly, a number of
authors attempted to use forms of relaxation or meditation as a control condition.
However , these "control groups " have been identified as active treatments within the
primary study and in subsequent research. Thus, the studies using relaxation controls are
actually comparison studies between two treatments . Because of their conceptual premise ,
commonly authors had developed a priori hypotheses only about the difference between
the so-called control group and the treatment group. Therefore, many of these studies
only reported a nonsigni:ficant finding for an independent t test. Nonsigni:ficant results can
be used to calculate an effect size if exact t and or p values are given. However , the
common practice for reporting non-significant results is with lower bounds ( p > .05) or
without numerical data (t = N.S.) Reporting results in this manner precludes the
calculation of effect sizes, and thus violates inclusionary rule (d). This is an unfortunate
loss of data and results in a relatively small number of articles being available for
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evaluation in the nonpharmacological treatment area. Those included are listed below by
categories in Tables 1 to 4. Lists of excluded can be found in Appendix C.

Data Collection

Once a study was identified as meeting all of the criteria for being included in the
current meta-analysis, it was coded for a variety of information (see Appendix D for
copy). Variables coded included sample used in the primary study, sample size, year the
study was published, percent female, type of control group used, randomized assignment,
mortality rate, and design of study (parallel or cross-over). In addition, quality of study
was coded in two separate ways. The first quality of study measure used is a researchbased instrument developed by Jadad et al. (1996). This instrument codes randomization,
double-blind features, and descriptions of dropouts . It been shown to have high inter-rater
reliability because of its objective descriptions of criteria (Jadad et al.). Scores for articles
being rated range from zero to five, with higher scores indicating a better quality report.
The second measure was created to examine quality issues specifically related to the
headache literature. Items include presence of wash-out or run in periods, types of
recording used, comparison groups used, type of setting, and control of medications/
treatments. This measure has scores ranging from one to three, with higher scores
indicating a better quality of report (see Appendix E for copy). This measure was checked
for inter-rater reliability by having a second PhD level psychologist code a randomly
chosen set of articles (approximately 15% of the total). The reliability coefficient for the
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Table 1

Primary Articles That Were Included in the Meta-Analysis for Propranolol
Authors
Ahuja & Verma (1985)
Albers, Simon, Hamik, & Peroutka (1989)
Andersson & Petersen ( 1981)
Borgesen, Nielsen, & Moller (1974)
Daho If ( 1987)
Diamond & Medina ( 1976)
Diener et al. (1996)
Forssman, Henriksson, Johannsson, Lindval, & Lundin (1976)
Havanka-Kanniainen, Hokkanen, & Myllyla (1988)
Johnson, Hornabrook, & Lambie (1986)
Kangasniemi & Hedman (1984)
Kangasniemi, Nyrke, Lang, & Petersen (1983)
Kjaersgard Rassmussen, Holt Larsen, Borg, Soelberg Sorensen, & Hansen (1994)
Kuritzky & Hering (1987)
Lucking, Oestreich, Schmidt, & Soyka ( 1988)
Ludin (1989)
Mathew (1981)
Mikkelsen, Kjaersgaard Pedersen, & Christiansen (1986)
Nadelmann, Phil, Stevens, & Saper (1986)
Pita, Higueras, Bolanos, Perez, & Mundo (1977)
Pradalier et al. ( 1989)
Rao, Das, Taraknath, & Sarma (2000)
Rosen (1983)
Sargent et al. (1985)
Standness (1982)
Stensrud & Sjaastad (1976)
Tfelt-Hansen, Standnes, Kangasneimi, Hakkarainen & Olesen (1984)
Weber & Reinmuth (1972)
Wilderoe & Vigander (1974)
Zeigler, Hurwitz, Preskorn, Hassanein, & Seim (1993)
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Table 2

Primary Articles That Were Included in the Meta-Analysis for Flunarizine
Authors
Al Deeb, Biary, Bahou, Al Jabeeri, & Khoja (1992)
Allias et al. (2002)
Bussone et al. (1987)
Freitag, Diamond, & Diamond (1991)
Frenken & Nuijten (1984)
Lamsudin & Sadjimin ( 1993)
Louis (1981)
Louis & Spierings ( 1982)
Lucking, Oestreich, Schmidt, & Soyka (1988)
Ludin (1989)
Mentenopolous, Manafi, Logothetis, & Bostantzoulou (1985)
N uti et al. ( 1996)
Pini, Ferrari, Guidetti, Galetti, & Sternieri (1985)
Rascol, Montastruc, & Rascol (1985)
Sorensen, Hansen, & Olesen (1986)
Sorensen & The Danish Migraine Study Group (1989)
Thomas, Behari, & Ahuja (1991)

Table 3

Primary Articles That Were Included in the Meta-Analysis for Divalproex Sodium Studies
Authors
Jensen, Brink, & Olesen (1994)
Kaniecki ( 1997)
Kinze et al. (2001)
Klapper ( 1997)
Lenaerts, Bastings, Sianard, & Schoenen ( 1996)
Mathew et al. ( 1995)
Rothrock, Kelly, Brody , & Golbeck (1994)
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Table 4

Primary Articles that Were Included in the Meta-Analysis on Nonpharmacological
Treatments
Combined
therapies
Thermal
biofeedback

Relaxation
therapy

Blanchard , Andrasik, Neff, Arena, et
al. (1982)

x

x

Blanchard et al. (1985a)

x
x
x

Author

Blanchard et al. (1985b)
Blanchard , Appelbaum, Nicholson, et
al. (1990)

x

x

Blanchard , Nicholson , et al. (1991)

x
x
x
x

x
x

Blanchard et al. (1978)
Daly, Donn, Galliher, & Zimmerman
(1983)
Gauthier, Lacroix , Cote, Doyon, &
Drolet (1985)

x

Gauthier, Cote, & French (1994)

x
x
x
x

Holroyd et al. (1995)
Holroyd et al. (1988)
Jurish et al. (1983)

TBF+

x

Blanchard , Appelbaum, Radnitz , et
al. (1990)

Blanchard et al. (1997)

EMG

x

x

(table continues)
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Author
Lake, Raney, & Papsdorf (1979)

Thermal
biofeedback

Combined
therapies
Relaxation ------TBF+
therapy
EMG

x

x

Largen, Mathew, Dobbins, &
Claghorn ( 1981)

x

McGrady, Wauquier, McNiel, &
Gerard (1994)

x

Mullinix, Norton, Hack, & Fishman
(1978)

x

x
x

Wauquier, McGrady , Aloe, Klauser ,
& Collins (1995)

overall score was .88, indicating that a high level of agreement between raters. This
suggests that this measure can be reliably used by different raters.

Analysis

After data were collected from primary studies, a variety of procedures were used
to evaluate the data for use in this meta-analysis. Analysis procedures will be described in
the following order: (a) standard effect sizes for continuous data, (b) odds ratios for binary
data, ( c) inclusion of cross-over studies for continuous and binary data, (d) homogeneity
model, and (e) inferential statistics used .

Effect Sizes for Articles Reporting
Continuous Data
Data from primary articles that are expressed in the form of continuous outcomes
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use means, standard deviations, and inferential statistics to report the outcomes of the
study. When this is the case the standardized mean differences were calculated. Glass,
McGaw, and Smith (1981) report procedures for this calculation in its simplest fomi as
g

=

(Mtreatment) - (M control )/SD pooled. Hedges and Olkin (1985) reported that this

formula results in a small sample bias and, thus , this meta-analysis used d as the estimator
of effect size (d= g(l - 3/4m - 1)), where m equals the degrees of freedom based on the
pooled standard deviation calculation. Throughout this meta-analysis , standard
procedures for estimating effect sizes were used as recommended by Hedges and Olkin.
All standard deviations used in calculations are pooled.
A key statistical issue in examining continuous data on migraine prophylaxis is
determining the appropriate statistical formula to use when paired data are presented in
the primary article. Most research on migraine prophylactics use a pre-post design, even if
a control/placebo group is being used . Formulas exist for calculating a paired t effect size
given the N, SD and paired t-statistic. However, this type of data (i.e., the N, SD and
paired !-statistic) is rarely presented in peer-reviewed journal articles. Dunlop , Cortina,
V aslow and Burke ( 1996) convincingly argued that the calculation for the standardized
mean difference using the independent t-test formula value can be substituted in lieu of the
paired-data formula. They argued that if the paired t test is used (which corrects for the
amount of correlation between the measures), the resulting ES estimate will be an
overestimate of the actual ES . Therefore, this meta-analysis employed the more
conservative independent t-test method when presented with paired data.
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Given the variety of statistical information provided in the primary articles
reporting continuous data, a hierarchy was developed to aid in consistent decision making
about statistical selection. Examples of all the below calculations can be found in
Appendix F. All continuous data calculations were performed with the aide of Meta-Stat

® computer program.

Decision Making About Effect Size Estimate
1. The "premiere" statistic is the standardized mean difference between two
independent samples .
2. If data to calculate the above is not provided , then an effect size estimate from

t, F, Z, or r will be used.
3. If 1 or 2 cannot be calculated , then an exact p estimate will be used to calculate
a Tscore .
4. If the groups being compared are a baseline average of several treatments , then
a pooled standard deviation will be calculated and the groups will be compared as if
independent.
5. A z-score conversion of percent improved will be calculated if appropriate data
are provided. A z-score conversion was only calculated on single-population studies if
there were three discrete assessment periods (a baseline, a placebo, and an active
treatment). Odds ratios are to be calculated in preference to z-score conversion if data are
present.
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Effect Sizes for Articles Reporting
Binary Data
The second type of data available in primary articles on migraine prophylaxis is
binary data. Medical research in the area of migraine headache commonly divides outcome
data into binary form. That is, researchers often report data for "responders" (those who
achieved a 50% reduction on some measure through treatment) and "nonresponders"
(those who achieved less than 50% reduction on some measure through treatment). This is
valuable data primarily because individuals are used as their own control, which lends itself
to a broader range of statistical analysis. The reduction of headache indices at the 50%
level is considered to be a clinically significant change and is used industrywide. The
procedure of reporting responder results also has draw backs. Namely, the data are
artificially dichotomized which results in the loss of exact data in some cases. That is,
those subjects who respond at the 48% level are treated the same as those who respond at
the 2% level. Likewise, those who respond at the 55% level are treated the same as those
who respond at the 100% level. Thus, binary data is less exact than continuous data and
carries less interpretive weight than continuous data. In the present study, more
confidence is placed in results obtained from continuous data (because they are considered
to be more representative of the primary findings) than in results gained from the binary
effect sizes.
Given that many studies initially selected for inclusion in this meta-analysis
reported binary data, a standardization statistic is needed so that it can be compared to
other studies. There are three alternative measures that are generally considered for
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standardizing binary outcome: the odds ratio, the risk difference, and the risk ratio. The
three statistics vary based on the measurement and use of absolute size difference and
relative size difference of treatment effect. The current meta-analysis reports binary data in
the form of odds ratio's (OR). Deeks (2002) reported that odds ratios are typically used in
case-control studies when disease prevalence is not known. In the current research the
baseline prevalence is unknown (i.e., the placebo or control rate of spontaneous
remission). Deeks reported that the use of relative risk ratios or risk difference ratios,
while potentially more intuitive, alters the effect measure by entering a false prevalence
rate that is not known and would "obviously be wrong, so odds ratios are the ideal" (p.
1598). The OR has a neutral statistic of "I," which indicates the odds ofreceiving
benefit/harm from the treatment is equal in both the control and the treatment group. As
the numbers approach infinity or "O," they indicate what the odds of benefit/harm are for
one group in comparison to the other. Thus, a .73 OR indicates that you have .73 ti.rnes
higher chance of getting benefit/harm in the first treatment than in the second. Values over
one simply indicate that the benefit/harm chance is higher in the second group than it is in
the first. If confidence intervals encompass the value of 1, then the chance of receiving
benefit/harm from the two treatments are considered to be nearly equal. When researchers
report OR they typically maintain one treatment group as the "anchor," in this study the
control was always the second treatment group, indicating that higher scores favor the
active treatment.
Once OR were calculated they were converted to Log-odds or the natural
logarithm of the OR. This converts the metric from an asymmetrical distribution that is
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distributed between zero and infinity to a symmetric statistic running from minus infinity to
plus infinity, with zero being the neutral value. This makes it easier to compare negative
with positive associations. And it is necessary in order to aggregate a total effect (Deeks,
2002). All OR were calculated with the assistance ofMetaAnalysis 3.0 ® by Alan Chang
2001. Examples of an OR calculation can be found in Appendix F.

Inclusion of Cross-Over Design Studies
In the past many authors of meta-analytic studies have chosen to disregard studies
that employ a cross-over design. A preliminary review indicated that 82% of metaanalyses at the Cochrane Controlled Trials Registrar do not include cross-over design
studies (Elbourne, Altman, Higgins, et al., 2002). This practice has been largely founded
on poor reporting of data in cross-over trials. Many primary studies choose to report
grand mean and standard deviations for treatment groups. This disregards the fact that
patients are their own controls, each patient has received multiple treatments, and means
are actually change scores and not independent group means. Thus, many conducting
meta-analyses have chosen to ignore data from cross-over trials.
Excluding cross-over data has come under fire recently due to the exclusion of
large numbers of studies that compare treatments ( e.g., Curtin, Altman, & Elbourne, 2002;
Elbourne et al., 2002). Theoretically, cross-over data is more robust than parallel data. In
addition, cross-over designs often compare two active treatments to each other.
Chambless and Hollon (1998) suggested studies that compare a new treatment to an
established treatment can be considered the premier type of efficacy research. Thus, the
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exclusion of cross-over design studies would lead to the exclusion of studies that are both
statistically and theoretically important. Consequently, it was determined that the present
study would include cross-over designs.
How cross-over designs should be included in a meta-analysis is a matter of
statistical debate. Three general options are available: (a) use pooled data from cross-over
studies and treat them as if the datum came from a parallel design (which results in an
underestimation of effect) ; (b) use data only from one phase of the cross-over design thus
making the study a parallel one (which results in an inflated Type 1 error); (c) include only
studies that report individual change scores , calculate the pooled variance estimate, and
calculate paired statistics effect sizes to adjust for the cross-over design (results in the loss
of a large number of studies).
The current meta-analysis employed a combined approach described in Elbourne et
al. (2002) for articles reporting continuous data. Primary studies that listed data on
individual patients or accurately provided paired data analysis were used to generate
Pearson's r statistics-for between group correlations (accounting for the fact that in a
cross-over design individuals are their own controls). The lowest correlation found among
primary articles was then substituted into the effect size calculation for the other crossover design studies within the same treatment type. An example of the substitution of a
correlation into a calculation for a standardized mean difference effect size can be found in
Appendix F.
Odds ratios require a different strategy when cross-over studies are included.
Given that OR already take into account the odds for a single individual on multiple
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treatments, correlations adjustments have not been found to alter the estimate of the
treatment odds (Elbourne et al., 2002) . Articles reporting binary data that were summed
across trial periods were used as if they were parallel.

Homogeneity Model
The selection of the appropriate summary statistic that represents the average
treatment effect size and corresponding confidence intervals for the meta-analysis is based
primarily on the issue of variance. Standard procedures for analyzing results of metaanalyses have traditionally been based on the assumption that there is one true treatment
effect being described by the meta-analysis (Fixed Effects Model). Under the Fixed Effects
Model (FEM) there is an assumption that any variation that occurs among study effect
sizes is caused by study variance accounted for by sampling error, patient characteristics,
or study characteristics (i.e., variance with-in the study). Summary statistics based on this
assumption assume that each study in the meta-analysis has the same underlying effect
(Brockwell & Gordon, 2001). That is, the FEM assumes that there is little study-to-study
variation and that the selection of studies is homogeneous.
In contrast the Random Effects Model (REM) assumes that the studies represent a
heterogeneous sample with two sources of variance--the variance within the study and the
variance between the studies. The addition of the between-study variation to the model
indicates that the primary studies each contribute (potentially uniquely) to the true effect.
Thus, the summary statistic becomes an indication of the general treatment effect that
centers around the true effect (Brockwell & Gordon, 200 I; Glasziou & Sanders, 2002).
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The two separate sources of variance allow for the assumption that the primary article
effect sizes are independent and normally distributed (Brockwell & Gordon). The REM
introduces an estimation of between study variance into all weighted averages to account
for a random model.
The choice between the two models can be made by testing for heterogeneity
between the individual effect sizes. The amount of heterogeneity between studies can be
tested through the use of the statistic defined by Cochran (1937) , which in practical form
IS:

~ w;(Y;"
Q,v= ~
µ")2 .

Where w = the inverse of the variance (or weight), Yi = the effect of each trial, and

µ=

the overall effect estimated from the meta- analysis. Thus, the calculation sums together
the weighted differences between overall effect size and the individual study effect sizes
(for an example of a calculation of a Cochran's Q see Appendix F). As the value of Qw
increases (results can range from zero to infinity), it indicates more study to study
variation. Cochran's Q is typically reported with a p value to indicate if heterogeneity is
considered to be more than would be expected by random sampling error. Thus, a
significant p value indicates that more heterogeneity exists than would be expected by
chance. The current study calculated Cochrane's Q for each treatment type. However, it
has been argued that the choice between FEM and REM should not be solely based on the
Cochran's Q (Brockwell & Gordan; Chang, Watemaux, & Lipsitz, 2001). In addition,
because this meta-analysis is comparing six separate treatments, it is important for a single
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model to be used consistently across treatment types. Thus, the current meta-analysis
applied a REM to all summary statistics. The FEM has been shown to have too narrow of
confidence intervals and to over-estimate the '"treatment effect" being described by the
meta-analyses. Larger confidence intervals and smaller effect sizes are likely to be
produced when using this model than when using the FEM (Brockwell & Gordan, 2001;
Curtin et al., 2002). The calculation of the Cochrans Q and summary statistics in the REM
model were calculated with the assistance ofMetaAnalysis 3.0 ® computer program
developed by AJan Chang 2001 .

Inferential Statistics

Rosenthal's file drawer calculation was calculated for each treatment study. The
file drawer phenomenon refers to a well-known publication bias toward significant results.
That is, publishers often only publish articles that report significant :findings.Articles that
do not report significant :findingsare often unpublished and left in the author's "file
drawer." Meta-analyses that only consider published articles are then basing results on a
biased sample. The Rosenthal's file drawer calculation is considered a rough guide for
determining the number of unpublished null :findingsthat would be needed to threaten the
:findingsof the meta-analysis on the published articles. Essentially, the Rosenthal's file
drawer test indicates if a finding of a meta-analysis is robust enough to stand against null
unpublished results. Each calculation is reported with the following: (a) an N, that
represents the number of null studies it would take to threaten the finding;, (b) a "credible

if' statement indicating that if the N is lower than the "credible if' number, then the
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findings may not be robust to the file drawer phenomenon; and (c) a probability level
based on a z score indicating the probability of finding a similar result by chance.
Regression analysis was used by treatment to identify study characteristics that
correlated with treatment effects. Pearson product-moment correlations were run to
identify significant associations between the study or sample characteristic and outcome.
Comparison of summary statistics across treatments through both visual comparison and
analysis of variance (ANOVA) were conducted to test for statistical differences between
summary statistics.
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CHAPTERV
RESULTS

The resuhs of the meta-analysis will be presented according to the following
sections: (a) results for Propranonol, (b) results for Flunarizine, (c) results for Divalproex
Sodium, (d) results for thermal biofeedback, (e) results for relaxation treatments, (f)
results for combination treatments, and (g) comparisons between summary statistics for all
treatments.

Results for Propranonol

Thirty-one effect sizes were calculated on a total of 30 studies for Propranonol
treatment. One study, Lucking et al. (1988), reported data on two separate trials so two
effect sizes were calculated from this study. Studies ranged in publication years from 1972
to 2000. The meta-analysis on Propranonol included 3,247 total observations, with 1,987
observations in the control group and 1,260 observation in the treatment group. Twentythree (74.2%) of the studies compared Propranonol to a placebo group. The other eight
used a control group rather than a placebo group. Reduction in the frequency of headache
was the most consistently reported outcome measure (27 of 31 ). Doses ranged from 60240 mg a day, with the mode being 180 mg a day. Modal active treatment length was 12
weeks (range 4 to 52 weeks). Mean Jadad quality score was 3.22, mean study quality
score was 2.48, mean mortality rate was 22%, and the study population was 74% female
(mean).
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Ten of the studies were parallel designs, the other 21 were cross-over designs.
Three articles provided enough information to calculate the correlation between groups
for cross:-over calculations. These were Borgensen et al. (1974) =.82; Mikkelsen et al.
(1986) = .81; and Stensrud and Sjaastad (1976) = .74. The lowest correlation (.74) was
substituted into the 18 other cross-over studies to account for the cross-over design issue.
Twenty-five studies provided enough continuous data to calculate standardized
mean differences. Odds ratios were calculated on the remaining six studies. Summary
statistics are listed below in Table 5 by category.
Regression analysis indicated that unbiased effect sizes varied systematically by
study design type, with cross-over studies producing significantly higher effect sizes than

Table 5
Findings for Propranolol
Statistic

Binary data

Continuous data

Q statistic

54.2989 p

REM summary effect size
REM summary CI (95%)

SMD = .68
(.54 - .81)

ln(OR) = 1.58
(1.08 - 2.07)

Variance

0.0044

0.643

Standard deviation

0.06667

0.2536

Rosenthal's file drawer

1122
Credible threat if< 135
p = 0.0000
z = 13.2711

=

0.0004

16.4264 p = 0.0057

146
Credible threat if< 40
p = 0.0000
z = 9.85
Note. SMD = Overall standardized mean difference score; ln(OR) = Overall natural
logarithm of the odds ratio.
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parallel design studies (R2 = .238, F= 7.89,p =.011). A significant correlation was noted
between unbiased effect size and study design type (r

=

.514), indicating that there is a

significant correlation between study design (cross-over or parallel) and effect size. See
Appendix G for full reporting of regression analyses and partial correlations.

Results for Flunarizine

Eighteen effect sizes were calculated on a total of 17 studies for Flunarizine
treatment. One study, Lucking et al. ( 1988), reported on two separate trials so two effect
sizes were calculated from this study. Studies ranged in publication years from 1982 to
2002 . The meta-analysis on Flunarizine included 1,702 total observations. With 1,030
observations in the control group and 672 observation in the treatment group. Eight
(44.4%) of the studies compared Flunarizine to a placebo group. The other 10 used a
control group or baseline rather than a placebo group. Frequency measures were the most
consistently reported measure ( 15 of 18). Doses ranged from 5-10 mg a day with the
mode being 5 mg a day. Modal active treatment length was 14 weeks (range was 4-24
weeks). Mean Jadad quality scores was 2.83, mean study quality score was 2.50, mean
mortality rate was 13% and the study population was 75% female (mean).
Fifteen of the studies were parallel designs, the other two were cross-over designs.
Fifteen studies provided enough continuous data to calculate standardized mean
differences. Odds ratios were calculated on the remaining three studies. Summary statistics
are listed below in Table 6 by category.
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Table 6

Findings for Flunarizine
Statistic

Binary data

Continuous data

= 0.4469

Q statistic

30.9889 p = 0.0056

1.6110 p

REM summary effect size

SMD= .68

ln(OR) = 1.4942

REM summary CI Interval (95%)

(.53-.83)

(0.73-2.25)

Variance

0.0057

0.152

Standard deviation

0.075

0.39

Rosenthal's file drawer

496
Credible threat if < 85
p = 0.0000
z = 11.4606
Note. SMD = Overall standardized mean difference score; ln(OR)
logarithm of the odds ratio

8
Credible threat if < 25
p = 0.0001
z = 3.7247
= Overall natural

Regression analysis indicated that unbiased effect sizes varied systematically by
treatment length, with treatments that were longer producing significantly higher effect
sizes (R 2 = .587; F = 17.07,p =.001). A significant correlation was noted between
unbiased effect size and treatment length (r = .733). See Appendix H for full reporting of
regression analyses and partial correlations.

Results for Divalproex Sodium

Seven effect sizes were calculated on Divalproex Sodium treatment. Studies ranged
in publication years from 1991 to 2001. The meta-analysis on Divalproex Sodium included
553 total observations, with 213 observations in the control group and 340 observation in
the treatment group. Six (85.7%) of the studies compared Divalproex Sodium to a
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placebo group. The remaining study used a control group rather than a placebo group. All
studies reported frequency outcome measures. Doses ranged from 500-2000 mg a day.
Doses were typically individually adjusted to be within optimal serum levels (50lOOmg/ml). Modal active treatment length was 12 weeks (range 6 to 24 weeks). Mean
Jadad quality scores was 2.57, mean study quality score was 2.14, mean mortality rate was
16.2%, and the study population mean was 83.7% female.
Five studies were of a parallel design and the other two studies were cross-over
designs. None of the articles provided enough information to calculate the correlation
between groups for cross-over calculations. Therefore, one cross-over study that provided
continuous data (Hering & Kuritzky, 1992) was discarded.
One parallel design study provided enough continuous data to calculate standardized
mean differences (Kinze et al., 2001). The standardized mean difference was 1.66. A
meta-analysis was not performed on this single effect size. Odds ratios were calculated on
the remaining six studies. Summary statistics are listed below in Table 7.
Regression analysis indicated that unbiased effect sizes did not systematically vary
by study design type, treatment length, quality scores, or by type of control groups used
(R2 = 1.00). No significant correlations were noted between any variable and unbiased

effect size. See Appendix I for full reporting of regression analysis and partial correlations.

Results for Thermal Biofeedback

Eighteen effect sizes were calculated on 15 studies for thermal biofeedback.
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Table 7

Findings for Divalproex Sodium
Statistic

Binary data

Q statistic

4.5794 p

REM summary effect size
REM summary CI (95%)

ln(OR) = 1.65
(1.20-2.11)

Variance

0.0535

Standard deviation

0.2314

Rosenthal's file drawer

80
Credible threat if< 40
p = 0.0000
z = 7.40

=

0.4693

Note. ln(OR) = Overall natural logarithm of the odds ratio.

Three studies (Blanchard et al., 1982, 1991; Jurish et al., 1983), were multi-arm studies
that allowed for two calculations to be made from each study. The thermal biofeedback
area of treatment can be broken into two protocols of treatment , one that includes explicit
relaxation training and one that does not. In this sample 14 effect sizes were calculated
from studies that explicitly taught some version of relaxation training (e.g., progressive
muscle relaxation, autogenic training) and 6 effect sizes were calculated from studies that
did not. Analysis of the findings indicate that results did not significantly vary with the
addition of relaxation to the standard thermal biofeedback protocol. Thus, results are
aggregated across these two categories.
Studies ranged in publication years from 1978 to 1997. The meta-analysis on
thermal biofeedback included 576 total observations , with 261 observations in the control
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group, and 315 observations in the treatment group. Fourteen (70%) of the studies
compared thermal biofeedback to another treatment. The other four studies compared the
treatment to a wait list group rather than an alternate treatment group. Ten effect sizes
were calculated from studies that compared thermal biofeedback to a control group. The
other eight effect sizes were calculated from within-group comparisons based on studies
that compared multiple nonpharmacological treatments. Effect sizes were calculated
separately for within-group studies and between group studies to identify if effects were
significantly different by study design. Studies that were compared to control groups had
an average effect size of .66 and studies that were comparison treatment designs with prepost measures averaged an effect size of .64. This suggests that comparison treatment
studies and controlled outcome studies for migraine prophylaxis are measuring a similar
effect . Thus , these two groups were summed for summary effect size calculation.
Headache Index measures were the most consistently reported measure (14 of 18).
Number of sessions ranged from 2 to 22 with the mode being 12. Modal treatment length
was 6 weeks (range 5 to 32 weeks). Mean Jadad quality scores was 1.66, mean study
quality score was 2.66, mean mortality rate was 15.22% , and the study population was
81 % female (mean).
All eighteen effect sizes were derived from parallel designs and fourteen studies
provided enough continuous data to calculate standardized mean differences. Odds ratios
were calculated on the remaining four studies. Summary statistics are listed below in
Table 8 by category.
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Table 8
Findings for Thermal Biofeedback

Statistic

Binary data

Continuous data

Q statistic

2.8813 p = 0.9983

3.1559 p

REM summary effect size
REM summary CI (95%)

SMD = .60
(.40-.79)

ln(OR) = 1.24
(1.08-2.07)

Variance

0.0098

0.148

Standard deviation

0.09899

0.03856

Rosenthal's file drawer

121
Credible threat if < 80
p = 0.0000
z = 6.0671

8
Credible threat if < 30
p = 0.0004
z = 3.3416

Note. SMD = Overall standardized mean difference score; ln(OR)
logarithm of the odds ratio.

=

=

0.3682

Overall natural

Regression analysis indicated that unbiased effect sizes did not vary systematically
(R 2 = .928, F = 3876 , p = .146). Variance for both binary and continuous data is very low

indicating that effect sizes were fairly uniform and did not vary by study characteristics.
No significant correlations were noted between unbiased effect size and any study
variable. See Appendix J for regression analyses and partial correlation tables.

Results for Relaxation Therapy

Five effect sizes were calculated for relaxation therapy. Treatments for relaxation
therapy included progressive muscle relaxation, autogenic training, and meditation.
Studies ranged in publication years from 1978 to 1990 (none after 1990 qualified for
inclusion in the meta-analysis). The meta-analysis on relaxation therapy included 186
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total observations, with 99 observations in the control group and 87 observations in the
treatment group. All five studies compared relaxation therapy to another treatment. Four
effect sizes were calculated from studies that compared thermal biofeedback to a control
group, while the other effect size was calculated from with-in group comparisons.
Headache Index measures were the most consistently reported measure (4 of 5). Number
of sessions ranged from 8 to 16, with the mode being 9. Modal treatment length was eight
weeks (range 5-37 weeks). Mean Jadad quality score was 1.83, mean study quality score
was 2.81, mean mortality rate was 13.8%, and the study population was 81 % female
(mean).
All effect sizes were derived from parallel designs. Four of five studies provided
enough continuous data to calculate standardized mean differences. An OR was calculated
on the remaining study. The OR for Daly et al. (1983) was 4.5584 with a confidence
interval of (0.88 to 23.37). The Log Odd was 1.51. Continuous data summary statistics
are listed in Table 9 below. Partial correlations for relaxations treatments can be found in
Appendix K.
Due to the small number or studies included in the meta-analysis a regression
analysis and partial correlations were not conducted.

Results for Combination Therapies

The results for the combination therapies include two major treatment categories:
EMG biofeedback and thermal biofeedback plus relaxation plus cognitive therapy (TBF +
R + Cog). Results will be presented on EMG biofeedback and then on TBF + R + Cog.
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Table 9

Findings for Relaxation Therapies
Statistic

Continuous data

Q statistic

6.1586 p

REM summary effect size
REM summary CI (95%)

SMD = .75
(.37 - 1.13)

Variance

0.0375

Standard deviation

0.1937

Rosenthal's file drawer

17
Credible threat if< 30
p = 0.0000
z = 4.4026

=

0.9770

Note. SMD = Overall standardized mean difference score.

Results for EMG Biofeedback
Combination Therapies
The selection criteria for EMG biofeedback resulted in a low number of studies
being kept for inclusion. Five different studies were identified for inclusion. Studies that
met the inclusion criteria for EMG biofeedback ranged in publication years from 1971 to
1994. The meta-analysis on EMG biofeedback included 97 total observations, with 51
observations in the control group and 46 observations in the treatment group. Three
(60%) of the studies compared EMG biofeedback to another treatment. The other two
studies compared the treatment to a wait list group rather than to an alternate treatment
group. Four effect sizes were calculated from studies that compared EMG biofeedback to
a control group, while the other effect size was calculated from with-in group
comparisons. Headache Index measures were reported in three of five studies whereas
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frequency measures were reported in two studies. Number of sessions ranged from 8 to 16
with the mode being 12. Modal treatment length was 5 weeks (range 5-16 weeks). Mean
Jadad quality scores was 1.45, mean study quality score was 2.62, mean mortality rate was
15.75%, and the study population was 88% female (mean). All effect sizes were derived
from parallel designs.
A total of five effect sizes were calculated for EMG biofeedback. EMG biofeedback
comes in two predominate forms; (a) EMG + Relax, or (b) treatment combined with
thermal biofeedback and relaxation training (EMG + TBF + R). In this sample three effect
sizes were calculated on EMG + TBF + R, and two effect sizes were calculated from
studies on EMG + Relax. Analysis of these five studies showed that the two different
protocols have distinctly different effect sizes and thus the results are reported separately.
Odds ratios were calculated on all studies . The results shown in Table 10 are for the only
two controlled studies available for EMG +Relax.Table

11 presents the findings for

EMG+TBF+R.
The following results are on the three controlled studies that reported treatment data
on EMG + TBF + R.
Regression analysis was not performed on these results due to the low study
numbers. However , effect sizes were fairly uniform within treatment protocols indicating
that effect sizes were unlikely to vary by study characteristic.

Results for Thermal Biofeedback plus Relaxation
Therapy plus Cognitive Therapy
A total of four different studies were identified for inclusion. Studies that met the
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Table 10

Findings for EMG + Relax
Statistic

Binary data

Q statistic

0.8119

REM summary effect size
REM summary CI (95%)

ln(OR) = 2.47
(4.0-.93)

Variance

0.6184

Standard deviation

0.786

Rosenthal's file drawer

4
Credible theat if < 20
p = 0.0005
z = 3.2693

p = 0.3675

Note. ln(OR) = Overall natural logarithm of the odds ratio.

Table 11

Findings for EMG + TBF + R
Statistic

Binary data

Q statistic

0.0086

REM summary effect size
REM summary CI (95%)

ln(OR) = 1.1064
(2.13-.075)

Variance

0.2765

Standard deviation

0.526

Rosenthal's file drawer

1
Credible threat if< 20
p = 0.0190
z = 2.0759

Note. ln(OR)

=

p = 0.9957

Overall natural logarithm of the odds ratio .
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inclusion criteria for TBF + R + Cog ranged in publication years from 1979 to 1990. The
meta-analysis on TBF + R + Cot included 112 total observations, with 49 observations in
the control group and 63 observations in the treatment group. All of the studies compared
TBF + R + Cog to another treatment. Three effect sizes were calculated from studies that
compared TBF + R + Cog to a control group, while the other effect size was calculated
from with-in group comparisons. Headache Index measures were reported in two of four
studies , frequency measures in two of four studies. Number of sessions ranged from 5 to
18, with the mode being 5. Modal treatment length was five weeks (range 5 to 12 weeks).
Mean Jadad quality score was 1.75, mean study quality score was 2.50 , mean mortality
rate was 14.25%, and the study population was 76% female (mean).
All effect sizes were derived from parallel designs. Three of four studies provided
enough continuous data to calculate standardized mean differences. An OR was calculated
on the remaining study. The OR for Lake et al. (1979) was 2.0370 with a confidence
interval of(0.18-21.94). The Log (OR) was 0.71. Continuous data summary statistics are
listed in Table 12 below.
Due to the small number of studies included in the meta-analysis, a regression
analysis and correlation analysis was not conducted.

Results of Comparisons Between
Summary Statistics

Results for comparisons between meta-analyses will be presented in two ways. First,
results are presented in table format for visual comparison. Deeks (2002) suggested that if
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Table 12
Findings for TBF + R + Cog
Statistic

Continuous data

Q statistic

1.1431

REM swnmary effect size
REM swnmary CI (95%)

SMD = 0.7260
(1.13-.31)

Variance

0.0442

Standard deviation

0.2102

Rosenthal's file drawer

6

p = 0.5647

Credible threat if < 25
p= 0.0005
z= 3.3080
Note. SMD = Overall standardized mean difference score.

summary statistics fall within each others' confidence intervals then treatments are roughly
equal. Thus, the effect sizes for treatments with more than one continuous outcome are
presented in Table 13. Then, results of an AN OVA (Table 14) conducted on the summary
statistics are reported . The summary results for ln(OR) data collected on treatments with
more than one binary outcome are then reported in Table 15, with ANOVA results in
Table 16.
Excluded in the swnmary analysis is the single continuous effect size found for
Divalproex Sodium (d = 1.66) and the single OR found for relaxation therapies
(In (OR)= 1.51) and TBF + R + Cog (ln (OR)= 0.71). Because these are single effect

sizes they do not represent a body of literature and, thus, are not included.
It should be noted that due to the nature of the two different types of data
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Table 13
Summary Statistics for Continuous Outcomes

Treatment

N

REM summary
effect size
(SDM)

Propranolol

25

0.68

.54- .81

Flunarizine

15

0.68

.53- .83

Thermal biofeedback

14

0.60

.40- .79

Relaxation therapy

4

0.75

.37-1.13

Combination therapy
TBF+R+Cog

3

0.72

.31-1.13

95% confidence
interval

Table 14
ANOVAfor Continuous Summary Statistics
Sum of
squares

df

variance

F

p value

Between-group

0.105

4

0.03

2.9024

0.0297

Within-group

0.51

56

0.01

Total

0.61
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(continuous and binary) not all outcomes could be directly compared to each another.

Only one type of effect size was calculated for each study. If the researchers provided
binary data, an OR was calculated; if continuous data were provided, a standardized mean
difference effect size was calculated . Therefore, in some cases a treatment category (e.g.,
Propranolol) will have some OR effect sizes and some standardized mean difference effect
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Table 15

Summary Statistics for Binary Outcomes

Treatment

N

REM summary
effect size
ln(OR)

Propranonol

6

1.58

1.08-2.07

Flunarizine

3

1.49

.73 -2.25

Divalproex Sodium

5

1.65

1.20-2.11

Thermal biofeedback

64

1.24

1.08-2.07

Combination therapy
EMG+Relax
EMG+ TBF + Relax

2
3

2.47

.93-4.0
.075-2.13

95% confidence interval

1.11

Table 16

ANOVAfor Binary Summary Statistics

Source

Sum of
squares

df

variance

F

p value

Between-group

2.29

5

0.46

3.1775

0.0314

Within-group

2.60

18

0.14

Total

4.89

23

s12es. Both types of data were found for Propranolol, Flunarizine, and thermal
biofeedback. Binary data only were found for Divalproex Sodium, EMG biofeedback plus
Relaxation, and EMG biofeedback plus thermal biofeedback plus relaxation therapy. Only
continuous data were used to calculate effect sizes for relaxation therapy and thermal
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biofeedback plus relaxation plus cognitive therapy. The result of including two types of
data is that the outcomes for some treatments types are not directly compared to other
treatment types. For example, Divalproex Sodium has one continuous effect size
(mentioned above) that was excluded and six binary effect sizes. The six binary effect
sizes are summed and reported in Table 15, resulting in Divalproex Sodium only being
compared to the other treatments that have binary outcomes. This excludes relaxation
therapy, which reported five continuous outcomes and is summed in Table 13. Thus,
Divalproex Sodium and relaxation therapy are not directly compared.
Indirect comparisons can be made by using the treatments that provided both types
of data. For example, Divalproex Sodium (binary) and relaxation therapy (continuous) can
be indirectly compared by directly comparing each to Propranolol (which provides both

binary and continuous outcomes). Through visual inspection it can be determined that
Propranolol and Divalproex Sodium have similar effect sizes and that Propranolol and
relaxation therapy have similar effect sizes; thus, Divalproex Sodium and relaxation
therapy are likely to have the similar effect sizes.
The results from the one-way ANOV A to compare continuous summary effect sizes
revealed a significant effect F= 2.902,p = .0297 (see Table 14). Post hoc Bonferroni
adjusted comparisons revealed no significant individual group comparisons (see Table LI

in Appendix L).
The results from the one- way ANOVA to compare groups revealed a significant
effect F= 3.1775,p

=

.0314 (see Table 16). Post hoc Bonferroni adjusted comparisons

revealed no significant individual group comparisons (see Table L2 in Appendix L).
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CHAPTER VI
DISCUSSION

The current meta-analysis was conducted to answer four questions: (a) How do
the effectiveness rates of treatments compare to each other and between groups
(pharmacological and nonpharmacological)? (b)What sample characteristics are
significantly correlated with outcomes? (c) Do outcomes vary if broken into two levels of
empirical evidence? (d) What information is available regarding short and long term
effectiveness rates for pharmacological and nonpharmacological studies? Each of these
questions will be addressed in tum. A discussion of the practical uses of these findings
follows. Then, limitations of the current findings will be discussed. Finally, suggestions for
future research in the area of migraine headache are proposed.

How the Effectiveness Rates of Treatments Compare
to Each Other and Between Groups

The results of the present meta-analysis suggest that five of the six evaluated
treatments have very similar effect sizes. In addition, the findings suggest that three of the
summary effect sizes (EMG biofeedback, relaxation therapy, and thermal biofeedback plus
cognitive therapy) are tentative due to a serious threats to validity from the file drawer
phenomenon. The evidence for these conclusions are reviewed below in the following
order (a) visual comparison of effect sizes, (b) Rosenthal's file drawer findings, (c)
inferential statistical findings, (d) findings for EMG biofeedback plus relaxation, (e)
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findings for EMO biofeedback plus thermal biofeedback plus relaxation, and (f) the
summary of the outcomes and possible explanations for findings.

Comparisons by Visual Analysis
The current meta-analysis compiled treatment effectiveness data on six
prophylactic treatments for migraine. The summary statistics presented represent the
results for the reduction of frequency or headache index for each respective treatment of
migraine headache. Summary statistics for continuous data range from .60 to .75. The
lowest summary effect size was found for thermal biofeedback treatment and the highest
summary effect size was found for relaxation therapy. All other treatments (Propranonol,
Flunarizine, Divalproex Sodium, and mixed treatments) had summary effect sizes that fell
within this range . All summary statistics fall within each other's confidence interval.
According to Gall, Borg , and Gall (1996), these effect sizes are in the large range of
treatment effectiveness.
Evaluation of the binary summary statistics also show two patterns. The majority
of the log (OR) statistics fall in a narrow range of effect sizes (1.49-1.65). Again, those
effect sizes that were clustered together all fell within one another's confidence intervals.
There are two exceptions for this pattern and they both involve EMO biofeedback. The
EMO biofeedback treatment has two protocols, one that includes thermal biofeedback and
one that does not. Analysis of the results revealed that when the protocols were split, the
EMO biofeedback treatment that included thermal biofeedback was low, log (OR)= 1.10,
and the EMO biofeedback that did not include thermal biofeedback was substantially
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higher, log (OR)= 2.47. The findings for EMG biofeedback represent the only effect size
that appears to be significantly different from the other treatments analyzed. Possible
reasons for all of these findings will be presented below following the discussion of the
inferential statistical results.

Rosenthal's File Drawer
Rosenthal's file drawer ratings for each treatment indicates that the file drawer
threat is a valid threat to the following treatments, Flunarizine (binary data only), thermal
biofeedback (binary data only), relaxation treatments, EMG biofeedback plus relaxation,
EMG biofeedback plus thermal biofeedback plus relaxation, and thermal biofeedback plus
relaxation plus cognitive therapy. The first two treatments, Flunarizine and thermal
biofeedback, are not seriously threatened by the file drawer phenomenon because the
continuous data provides more than enough findings to support the conclusions in the
published research. Therefore, the results for Propranonol, Flunarizine, Divalproex
Sodium, and thermal biofeedback are considered to be stable results that could not be
easily threatened by nonpublished studies that show no difference between the treatments
and control groups.
However, the other treatment results (EMG treatments, relaxation treatments, and
thermal biofeedback plus relaxation plus cognitive therapy) are potentially threatened by
nonpublished studies that support the null hypothesis. Thus, less confidence can be placed
in the findings for EMG treatments, relaxation treatments, and thermal biofeedback plus
relaxation plus cognitive therapy. This is largely due to the small number of studies used
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to find the summary statistic in each of these treatments. Of particular concern are the
results for the EMG biofeedback plus thermal biofeedback plus relaxation treatment that
indicates that only one unpublished article (that finds support for the null hypothesis)
could be a valid threat to these results. So, while the present findings are suggestive of the
basic trend for these treatments, there is not enough data to form solid conclusions about
their treatment effect without further replication of outcome findings.

Comparisons by Inferential Statistics

Inferential statistics were used to compare effect sizes to one another. ANOVA
procedures were conducted to attempt to identify statistically significant differences
between the summary statistics. Results from the ANOV A indicated that there was a
significant difference between the summary statistics for both the continuous data (F =
2.90 ;p

=

.029) and binary data (F = 3.l 7;p

=

.031). Post-hoc analysis with Bonferroni

corrections were performed. None of the post-hoc analyses reached significance. This is
likely due to the large number of comparisons that were conducted between the groups.
By performing approximately 10 comparisons for each group of outcomes the significance
value with Bonferroni correction becomes p < .005 (continuous) or p < 003. (binary). This
is an extremely stringent test and these treatments did not reach the criterion.
It should be noted that several authors warn that using inferential statistics is highly
inappropriate for meta-analyses (e.g., Abrarni, Cohen, & Apollonia, 1988; Schmidt, 1992).
They argue that the nature of effect sizes violate the assumptions of inferential statistics
(i.e., they are not samples of the population, they are the population; they do not meet the
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assumptions of normal distributions, etc.) . In addition, they report that inferential statistics
are inappropriate for measurement based on the individual unit; effect sizes that are
weighted (as are all summary statistics used under the random effects model) result in a
statistic that is based on the individual. The current meta-analysis is likely to have been
effected by these issues. In the present meta-analysis a specific population of interest was
defined a priori (i.e., through the use of inclusionary rules such as migraine prophylactic
studies that examined one of six treatments, providing enough data to calculate an effect
size, etc.) . A systematic search strategy was used to attempt to obtain all studies that made
up the defined population. As a result, the use of inferential statistics would be
inappropriate in the current meta-analysis to the same extent that the efforts to obtain all
articles were successful. Thus , the results of the ANOVA ' s and post-hoc Bonferonni
calculations in the current meta-analysis may be invalid due to assumption violations and
should be interpreted with caution.

EMG Biofeedback Plus Thermal Biofeedback

The low ln (OR) summary statistic for EMG biofeedback plus thermal biofeedback
is not as interpretively important as the meaning of this treatment's confidence interval.
When a ln (OR) confidence interval encompasses zero it can represent that a treatment has
no greater effect than the comparative treatment (in this case, a control group). It should
be noted that the EMG biofeedback plus thermal biofeedback confidence interval is the

only treatment that has a confidence interval that approaches zero (.075). If the true
treatment effect for EMG biofeedback plus thermal biofeedback lies in the lower end of
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the confidence interval, it would indicate that the odds of an individual having a successful
outcome with this treatment may be equal to the odds of a placebo outcome.
Statistically, the wide confidence interval found for EMG biofeedback plus thermal
biofeedback (.075-2.14) indicates that there is more variability in this summary effect size
than in some of the others. Close examination of the findings for EMG biofeedback plus
thermal biofeedback indicates that the three primary effect sizes that make up the overall
summary effect size are similar to each other and to the summary effect size (ln (OR)=
1.10, 1.06, and 1.16; REM summary effect size In (OR) = 1.11) . Thus, the variation
between studies is quite low. However, the confidence interval calculated using the
random effects model takes into account within study variation as well as between study
variation. Thus, this large confidence interval was likely effected by the within study
variance. Of particular note is the within study variance found for Largen et al. (1981),
the standard deviation of within study variance for this study was 1.21, the two other
effect sizes for EMG biofeedback plus thermal biofeedback had standard deviations at .80
and .85. Indicating that the Largen study introduced much of the within study variability
found in this summary effect size.
The high level of variability in Largen et al. ( 1981) may be explained by the
sample sizes or the small effects that were reported. The Largen study has particularly
small sample sizes (experimental group N = 6, control group N = 5); small sample sizes
can introduce more variability into the ln (OR) effect size calculations than larger sample
sizes. In addition, the Largen study had only three successes in the experimental group
(three of six), indicating that the odds of success in this condition were not greatly in favor
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ofEMG biofeedback plus thermal biofeedback. These two added sources of variation
may have widened the ln(OR) effect size confidence interval and may explain this finding
in the current meta-analysis.
The summary effect size in for EMG biofeedback plus thermal biofeedback (In
(OR)= 1.11) is also low. The poor outcome for this type of treatment may have been
influenced by several major factors; number of studies used to calculate the treatment
effect, study characteristic, or a lack of a true treatment effect. Each of these possibilities
is explored below.
The summary statistic for EMG biofeedback plus thermal biofeedback is based on
a small number of studies (N = 3). However, EMG biofeedback plus relaxation is based on
only two studies, and the resulting summary statistic does not display a problematic
confidence interval. Second, the poor outcome for EMG biofeedback plus thermal
biofeedback may represent a study design flaw that negatively impacts the treatment
outcome. An analysis of the studies used to find the summary statistic for EMG
biofeedback plus thermal biofeedback shows that all three studies used control groups
instead of wait list groups. It is possible, given difficulty finding appropriate attention
placebo groups, that these control groups were flawed and systematically bias the
outcome of this analysis.
Examination of the individual studies indicates that one study used thermal
biofeedback with temperature cooling as a control and the other two used groups that
were told to relax daily. Both could bias findings by providing a treatment effect in the
control groups. Temperature cooling has a mixed history of effectiveness. Several authors
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(Blanchard et al., 1997; Gauthier, Bois, Allaire, & Drolet, 1981) have reported that
temperature cooling biofeedback can be equally effective to thermal warming biofeedback.
However , it is a commonly held belief that thermal biofeedback with a focus on
temperature cooling is counter intuitive to migraine pathophysiology and is ineffective
(Largen et al., 1981). The other two primary studies used to establish the effect size for
EMG biofeedback plus thermal biofeedback had control groups that were "self-relax"
groups. The self-relax groups were instructed to "relax" 10-15 minutes a day. There is a
known treatment effect for structured daily relaxation technique. While these studies did
not use structured techniques , the self relaxation instructions given to subject s may have
resulted in a small treatment effect for the control group. Given that all three of the
control groups have at one time been considered an active treatment on migraine
headache , the "control" group participants in these studies may have benefitted to some
degree from the instructions they were given, thereby reducing the difference between the
two groups and decreasing the resulting OR. Anecdotal review of the studies used to
calculate the summary effect size for EMG biofeedback plus thermal biofeedback lends
support to this hypothesis. Each study in the EMG biofeedback plus thermal biofeedback
treatment group reported that 20-30% of participants in control groups reached the
success criteria (50% reduction in frequency of headache). This can be compared to the
studies used in the EMG biofeedback plus relaxation treatment group who each report
between 16-18% of participants in the control groups met the success criteria.
Finally, the low effect size found for EMG biofeedback plus thermal biofeedback
may reflect a true treatment effect. The three studies that utilized EMG biofeedback plus
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thermal biofeedback all included initial sessions ofEMG biofeedback that were followed
by thermal biofeedback training. It is possible that the initial EMG biofeedback training in
some way interfered with the typically good outcome of the thermal biofeedback
treatment.

EMG Biofeedback plus Relaxation Techniques
The ln (OR) summary statistic for EMG plus relaxation techniques is 2.47. This is
the highest binary summary statistic found in the current meta-analysis. This summary
statistic also has a large confidence interval (.93 - 4.0) The summary statistic is based on
only two studies, they both resulted in high ORs but are somewhat different from each
other (primary study ln (OR) = 2.11 and 3.86) , which would account for the confidence
interval. The high level of treatment effect noted for EMG biofeedback plus relaxation
training may have been influenced by the fact that both studies have relatively early
publication dates (1979 and 1983), both included mixed headache patients, and both had
very low quality ratings. In addition, one of the studies (Daly et al., 1983) was not
randomized, the subjects were assigned to groups based on the severity of their symptoms.
These study characteristics may have introduced bias that inflated the EMG biofeedback
plus relaxation treatment effect size.

Summary of Outcomes

The findings of this meta-analysis indicate that five of the treatments evaluated
produce moderate to large effect sizes. The one exception to this finding is the relatively
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large effect size for EMG biofeedback plus thermal biofeedback. However, it is likely that
the findings for EMG biofeedback were unduly influenced by study characteristics. This
study's findings regarding effect sizes for these five treatments for migraine are nearly
identical to those found by the Duke University study conducted for the Department of
Commerce (Duke University and Center for Clinical Health Policy Research, 1999a,
1999b). These studies reflect the same :findingsalthough some of the statistical and
selection procedures varied. This "replication " of the Duke University study offers strong
support for the finding that these treatments offer similar moderate-to-large rates of
effectiveness.
It is curious to find that five different treatments based on highly varied theories

and approaches have approximately the same treatment effect for migraine prophylaxis.
Results based on OR indicate that between 40-70% of the subjects in clinical trials reach
clinical reduction of symptoms (i.e., 50% reduction in frequency or headache index) no
matter what treatment they receive. These :findingsbeg the question, "Why do these
treatments all have approximately the same effect when they are so different?" While there
is no succinct answer to this question, there are important factors that may contribute to
this finding. The first factor impacting the treatment effects may be compliance. Second ,
migraine, as currently defined, may represent a set of disorders, some of which are
amenable to the types of treatments currently being used and others that are not being
affected.
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Compliance
Compliance has long been an issue for all long term treatments. Mullemers,
Whitmarsh, and Steiner (1998) indicated that compliance in migraine prophylaxis is a
major issue. They report that through the use of a computer monitoring system (secretly
inserted into the lids of patient pill bottles) they were able to identify the actual compliance
of subjects receiving migraine prophylactic treatment. Mulleners et al. (1998) reported that
the used-on-schedule compliance rate (even in a controlled study) was, on average, 30%
for participants who were to take medication two or three times a day
(N = 18). Participants who took medications once a day averaged 66% used on schedule

compliance rates (N = 11). The authors suggested that these low compliance rates
significantly altered the effect of medical treatments intended to reduce the frequency of
migraine. It is theoretically possible to extend these results to the nonpharmacological
treatments for migraine. If patients have difficulty accurately taking a medication one to
three times a day, it is questionable if they will adequately practice biofeedback techniques
or relaxation techniques at 10-15 minutes per day.
Mulleners et al. ( 1998) also found that patients were remarkably inaccurate about
reporting to researchers how many pills they took. Even with a known compliance check
(counting remaining pills) they found that there was a large difference between the amount
of pills actually taken and the amount of pills reported to be taken. This :findingseriously
calls into question the results of studies reporting nearly perfect compliance with treatment
regunes.
If compliance rates are as low as suggested by Mulleners et al. ( 1998), then it may
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account for why none of these varied and sometimes intensive treatments have reached a
desired level of effect or been able to differentiate one treatment from another. In addition,
these :findingshave "real world" implications for how usable daily treatments are for the
general population. If subjects cannot partake of treatment in a prescribed manner during a
highly controlled and structured situation, it is not very likely that they will appropriately
engage in treatment under everyday living situations.

Migraines as a Broad Category
The current meta-analysis finds that treatments ranging from structured guided
relaxation to calcium channel blockers have similar effects in migraine prophylaxis. It is
possible that the finding of equivalent treatments effects indicates that more than one
disorder is being treated by the migraine prophylactic treatments. Thus , chronic migraine
headaches may be indicative of several different physiological and psychological pathways.
If different disorders are currently grouped into the "migraine" category, and each

treatment addresses a different underlying condition, it could account for the :findingsof
similar effect sizes.
Recent genetic research may offer some support of this hypothesis. Although
identifying genetic markers for diseases is still in its infancy as a science, some interesting
:findingsregarding migraine headaches have already been reported. For example, Goadsby
( 1997) reported that familial migraine has been linked (in some families) to chromosome
19pl3. Goadsby went on to report that preliminary :findings suggest that different families
may be linked to other chromosomal regions. Of particular interest has been the finding
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that for those who have a link to chromosome l 9p 13 some also have links to lower
channel genes that are voltage-gated ionophores for Na+ and or K+. Flunarizine and
Divalproex Sodium both have Na+ and Ca+ ion effects. Thus, these treatment may only
work for those who have the particular genetic profile that is associated with Na+ deficits.
As the area of genetic research broadens it may identify other familial deficits that best
account for treatment effects of these and other types of treatments.
While different types of migraines may exist , it appears that migraines are likely to
all share common physiological pathways. If they did not , the current treatments would be
unlikely to treat the noted large numbers. Goatsby ( 1997) reviewed experimental human
and animal research and identified the common pathways that pharmacological agents
share. Most prominent were the 5HT receptors and the calcium or sodium channels .
Goatsby reported that most prophylactic pharmacological agents impacted at least one of
th e seven subclasses of 5HT receptors.

Goatsby reported that Methysergide , Pizotifen,

Propranolol, Amitryptiyline, Imipramine, and Flunarizine had documented effects on the
5HT system. Alternatively, Goatsby noted that Flunarizine and Divalproex Sodium had
documented effects on the active sodium and calcium ion channels .
Nonpharmacological treatments have less experimental data available in the
research. However, several authors hypothesize that nonpharmacological

treatments

promote biological homeostasis that reduces the likelihood that the above mentioned
systems will be negatively impacted ( e.g., Blanchard et al., 1978; Feurstein, Bortolussi,
Houle, & Labbe, 1983). Holroyd (2002) reported that cortical excitability has been
strongly linked to the onset of migraine. Thie; excitability (related to neurogenic
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inflamation that sensitizes nerve endings) can be altered through psychophysiological
interventions that seek to quiet the system and thereby reduce brain stem activity
(Holroyd). The brain stem has been implicated as the "migraine generator" due to its role
in pain reception and vascular control (Weillner et al., 1995). Holroyd suggests that
nonpharmacological treatments may be nonspecifically reducing the reactivity of the brain
stem, making this a likely choice for the common pathway mechanism that the
nonpharmacological treatments share.
Goatsby (1997) focused mostly on pharmacological treatments; however, his
comments on available research can be applied to both areas (pharmacological and
nonpharmacological treatments) .
The understanding of the action of preventative drugs is at a relatively immature
stage. Recent developments in pharmacology and studies of pathophysiology of
migraine have provided a substrate around which concepts can be developed. The
actions and indeed the locus of action of the preventatives is crucial since these
drugs are likely to point io the basic defect which underlies the process responsible
for a migraine attack. (p. 90)
Thus, suggesting that the common pathways that the pharmacological treatments share is
a crucial yet undeveloped area of understanding. This statement can be applied to the
understanding of the common pathways of nonpharmacological treatments, that are also in
their infancy. Future research on how migraine prophylactic treatments work can help
develop clearer understanding of migraine pathogenesis and would help to clarify why the
treatments in the current meta-analysis have nearly identical effects .
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Sample Characteristics That Are Significantly
Correlated with Outcomes

The current meta-analysis found that only two treatment groups displayed sample
characteristics that significantly correlated with outcome. Study design significantly
correlated with outcome for Propranonol and treatment length significantly correlated
with outcome for Flunarizine. No other significant :findings for study characteristics were
found. Notably , study quality was not among those sample characteristics that correlated
with outcome . Below, significant :findingsfor Propranonol and Flunarizine are discussed ,
followed by a discussion of study quality.

Propranonol and Study Design
The regression analysis for Propranonol treatment outcomes for migraine
prophylaxis identified that effect size outcome was significantly corr elated with study
design. The finding indicated that cross-over designs produced higher effect sizes than
parallel designs. This finding may be largely due to the method of including cross-over
studies in this meta-analysis . The lengthy history of Propranonol as a migraine
prophylactic has resulted in years ofresearch examining Propranonol's effects versus other
pharmacological agents. This has resulted in a high number of primary articles that have
cross-over designs. As previously mentioned, the results from cross-over designs have
typically been ignored in meta-analyses. The current meta-analysis attempted to include
the results by using a correlation in the calculation of effect size. When a correlation is
included in the calculation of effect size the result is always of greater magnitude than
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uncorrelated effect size correlations. Thus, it is not surprising to find that the two types of
study designs produced systematically different outcomes.
However, researchers have suggested that it is appropriate for cross-over designs
to yield more powerful results than parallel designs (Kunkel, 1987). Cross-over designs
are considered to hold at least twice the power of parallel designs because participants
serve as their own control and their own comparison. The current meta-analysis chose a
conservative approach to this issue. Correlations were gathered from all studies providing
them and correlations were calculated for all studies that provided individual data. The
lowest correlation obtained was substituted for all cross-over studies (even if the original
study provided a higher correlation). Thus, the finding that cross-over studies have higher
effect sizes may be a product of the statistical procedures used in this analysis. The
example of effect sizes for cross-over studies were calculated in Appendix F. It is clear in
the example that the effect size is larger when the correlation is added in. Thus, the
finding that cross-over designs had higher effect sizes is not surprising given that a priori
decision to add more ''weight" to these studies by using correlations with all effect size
calculations for cross-over designs.

Flunarizine and Treatment Length
The current meta-analysis found that effect sizes increased as length of treatment
increased for subjects who were treated with Flunarizine. This is not surprising given that
Flunarizine makes plasma levels increase slowly with daily oral administration. Serum
levels do not reach a steady state for 4 to 6 weeks (Todd & Benfield, 1989). This indicates

'
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that it takes a longer time to reach a ''therapeutic dose" level in the patient . The slow
effect ofFlunarizine is supported by the current outcome findings. Many of the original
research articles on Flunarizine attempted to use the Propranonol research protocol that
often treated patients for 8 to 12 weeks . Flunarizine's full effect seems only to begin to
appear between 8 and 12 weeks. Thus, later research shifted to a 16- to 20-week protocol ,
with positive results . This appears to account for the finding that Flunarizine' s effect size
seem to grow with length of treatment.

Quality of Study

The current study did not identify any statistically significant relationships between
quality of study (as measured in this analysis) and outcome. The lack of association
between quality of study rating and outcome is likely due to the selection criteria used in
this meta-analysis. That is, the selection criteria were fairly rigid and may have selected a
fairly homogenous group of articles. There were two quality rating scores obtained for
each article included in the meta-analysis. The first was the Jadad Quality Score and the
second was an author -developed study quality rating score. Quality of study in the current
meta-analysis was defined in two ways: (a) quality of study as defined by Jadad et al.
(1996) is defined as how much the authors report the use of high quality study design
procedures (i.e., random assignment, double blinding, and description of dropouts), and
(b) quality of study is defined by how well the authors addressed concerns related to
migraine prophylactic treatment. The scale used to assess the first component of study
quality was proposed by Jadad et al. and has been shown to have good inter-rater
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reliability and has been empirically validated as an assessment tool for study quality. The
authors report that the instrument has been shown to be used consistently by raters
regardless of background or training, indicating that it is likely to be valid and reliable in
multiple settings including the current one.
The second quality score has a high inter-rater reliablity (reliablility coefficient was
found to be .88). However, it has not been empirically validated. The quality score has
face validity as it is based on the recommendations of the authors who were reviewed
earlier. There it was identified that migraine prophylaxis treatment outcomes were often
impacted by the following: type of measurement used (Holroyd & Penzien, 1990), type of
control used (Compas et al., 1998), study design (Holroyd et al., 1991), use of run-in/
washout periods (Bogaards & ter Kuile, 1994) , multiple setting measurement (Bogaards
& ter Kuile) , use of a comparison to another active treatment (Chambless & Hollon ,

1998), controlling other medication (Onghena & Van Houdenhove , 1992), and measuring
compliance or home practice (Holroyd & Penzien).
Each of the above variables were believed to pose threats to validity of reported
outcomes in a study on the quality of a migraine prophylaxis outcome. However, the way
these variable were rated (as dichotomous, either present or not) and summed (with some
variables being seen as necessary and other being seen as important) has not been
validated. The two quality of study ratings did reach similar results (no correlation
between outcome and study quality) which may indicate that they both are measuring the
same broad construct of study quality. Nevertheless, the only conclusion about quality of
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study that can be drawn from the current meta-analysis is that quality of study as measured
in this meta-analysis did not significantly correlate with treatment outcome.
It should be noted that there were differences between treatments in the mean

quality rating score . The following mean quality scores were obtained for each treatment
(Jadad Quality Rating Scores are listed first, then study quality rating scores) , Propranonol
(3.22, 2.48) , Flunarizine (2.83, 2.50) , Divalproic Sodium (2.57 , 2.14 ), thermal
biofeedback (1.66 , 2.66) , relaxation treatments (1.83 , 2.81) EMG (1.45 , 2.62) and thermal
biofeedback plus cognitive therapy (1. 75, 2.50 ).
The Jadad Quality Score ranges from O -5. These scores indicate to what degree
the researchers used appropriate research design to rule out threats to validity. The scale
rates each article on the following: random assignment (up to 2 points) , double-blind
design (up to 2 points) and description of drop outs (1 point). Average scores above 3 on
this scale are likely to indicate studies of high quality that have relatively few validity
threats as a result of study design . The only treatment that exceeded an average Jadad
score of 3.0 was Propranonol (3.22). An average score between 2 and 3 represents a
group of studies that may have more significant threats to validity as a result of study
design or may have had inadequate published reporting of the study design. Both
Flunarizine (2.83) and Divalproic Sodium (2.57) fall into this category. A score below 2
on the Jadad Quality Scale indicates a group of articles whose findings may have serious
threats to validity due to study design. All the nonpharmacological studies fall into this
category, this is due to the lack of"'double blinding." None of the behavioral articles
received credit for double blinding, reducing the scores of all behavioral studies by at least
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2 points. Double blinding is a proposed research technique that is designed to reduce the
effect of experimenter/participant expectation on outcome. The ability to actually achieve
true double blinding is questionable. It has been argued (e.g., Kirk-Smith & Stretch, 2001;
Turner, Jensen, Warms, & Cardenas, 2002) that treatment providers (nurses, doctors,
etc.) and participants in pharmacological treatment evaluation studies with double-blind
conditions are able to guess which treatment condition they are in (experimental or
placebo). Thus, potentially invalidating attempts to double blind the study. Doubleblinding becomes even more problematic when nonpharmacological treatments are
considered. Some authors (e.g., Lukoff, Edwards, & Miller, 1998) have argued it is nearly
impossible to double blind a nonmedical intervention that involves providing an officebased intervention. Whether possible or not the attempts at double blinding in the field of
psychological and behavioral research appear to be very low. Sheldrake (1998) reported
that in a review of the top psychological journal only 9% of experimental articles use a
double-blind methodology. This low use of the double-blind methodology is reflected in
the nonpharmacological study of migraine prophylaxis. The nonpharmacological treatment
results must be interpreted with caution due to the limited use of double blinding.
The second type of quality rating used in this meta-analysis was developed by the
current researcher and was based on previous literature reviews on migraine prophylactic
treatments. The Jadad Quality Rating scale focuses on characteristics of standard study
design, the second quality rating focused on variables that spedifically pose validity threats
in headache outcome studies. For example, did the researchers include a wash-out period
in which participants were withdrawn from other medications so that the experimental
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treatment alone could account for treatment effect? This quality rating score ranges from 1
to 3, with 3 representing the highest quality score. The quality ratings for the treatments
examined were fairly consistent across treatment type. The mean scores ranged from 2.14
to 2.8, indicating that the articles included in this meta-analysis fairly consistently
attempted to control for variables that are known to impact treatment outcome in migraine
prophylaxis.

Do Outcomes Vary if Broken into Two Levels
of Empirical Evidence?

Chambless and Hollon ( 1998) suggested that the "premiere" type of outcome
research compared a treatment that was known to be effective to one that was being
tested. They suggested that a treatment reported to be better than placebo revealed
nothing about how it compared to other available treatments and thus was not as useful.
The current meta-analysis attempted to identify whether this premiere type of research
actually provided different information or just more convenient information. To address
this issue placebo/control groups were coded separately from comparison group studies.
This variable (along with other identified variables of interest) was entered into regression
analysis for each treatment to identify if treatment outcome systematically varied by the
type of comparison group (control vs. active treatment). The findings of the present metaanalysis indicated that none of the regression analyses included the variable '"treatment
comparison group" as a significant variable related to outcome (see Appendices G, H, I,
and J). Thus, in the area of migraine prophylaxis, the type of outcome information
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provided by comparison research studies was similar in magnitude to the information
provided in placebo/controlled studies.
In the area of migraine prophylaxis treatment outcome identifying the premiere
type of research may depend largely upon how the author reports the results. Migraine
prophylactic treatments, as shown in the present meta-analysis, have very similar treatment
outcomes. Thus, comparison studies do little to enlighten us about which treatment is
better , rather they merely confirm that there is no statistical difference between treatments.

If the author chooses to only report nonsigni:ficant results between two active treatments,
then the results of comparison research studies cannot be synthesized with other research
studies. Such reporting makes comparison research studies less "useable" than
placebo /controlled studies. Thus , Chambless and Hollon's (1998) suggestion that
comparison studies are the most valuable way to compare studies may only be true when
there is comprehensive reporting ofresults. If this is not the case, articles that provide
effect size information are equally useable regardless of whether a comparison group was
used or not.

Information Available Regarding Shortand Long-Term Effectiveness

The current meta-analysis coded for length of treatment and length of follow-up.
Each treatment varied in the amount of long-term data that was collected. Overall, all six
treatments showed that effects of treatment were maintained as long as treatment was
maintained. Most treatments examined in the present meta-analysis have studies showing
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up to 6 months of treatment with positive outcomes. However, examination of treatment
effects after discontinuation of treatment is difficult to determine. The methodological
problems of determining long-term effects for a previous treatment for migraine will be
discussed below. Followed by a discussion of known long-term effects of treatments
evaluated in the present meta-analysis.

Methodological Problems

Data on migraine prophylactic treatments after the treatment has been discontinued
are valuable . However , studies that attempt to follow up on a migraine prophylactic
treatment face some inherent problems. First, it is unethical to maintain control groups for
long periods of time when known treatments exist. Second , without a control group it is
impossible to tell if the reported levels of symptomology are related to the previous
treatment or the waxing and waning nature of migraine. Wnen long periods of time are
involved it is nearly impossible to rule out alternative explanations for reductions of
reported symptoms from baseline. Finally, the selection process in follow-up studies is
flawed due to unavoidable selection bias. Each of these issues are addressed below .
The issues related to the lack of control groups for long-term outcomes is a
significant one. First, it is considered unethical to withhold treatment from a control group
once the active phase of the treatment has been discontinued (Sorbi, Tellegen, & DuLong,
1989). Therefore, many researchers offer the active treatment to control subjects after the
first phase of the study discontinues. Once the subjects have been treated, there exists no
treatment-free group with which to compare the results of patients after a certain amount
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of time has elapsed. The absence of a control group precludes the calculation of an effect
size for inclusion in a meta-analysis.
Second, the absence of a control group in a long-term prophylactic treatment
outcome study for migraines is particularly problematic due to the nature of migraine
headaches. Migraine is considered to be a cyclical condition in which cycles of migraines
occur and remit in an unpredictable fashion (Couch, 1987). Symptoms of migraines are
highly variable and can include intense periods of :frequent migraines and extended periods
without migraines. Couch reported that between 28-60% of migraine sufferers have
symptoms that remit with placebo treatment. Thus, when long-term studies report that
treatment gains are maintained or improved at three years, it is difficult to determine if the
effects are actually related to the initial treatment , or, if, in the normal course of migraine,
the symptoms have simply remitted.
A third related issue is the possibility of alternative explanations for treatment
effects that are not due to the course of migraine itself It is impossible to control for all
historical, maturational, and alternative treatment effects over an extended follow-up
period. The possibilities for alternative explanations are nearly endless. A subject may have
moved, tried an alternative treatment, married, changed jobs, had children, or had children
leave the home. When these issues are not controlled via randomization and controlled
comparison groups it is difficult to connect the level of symptomology to a previous
treatment.
Finally, selection bias becomes an issue in follow-up studies. Researchers generally
only include results of those subjects that can be contacted. It is rare that all subjects who
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participated in the initial research study can be contacted. Thus, it is possible that those
who are available are significantly different than those who are not. In addition, many
researchers complicate the issue of selection bias at follow-up by attempting to contact
only those who had a positive outcome to the initial treatment. While intuitively appealing,
this procedure selects for not only those who had positive effects, but also for those who
can still be reached. This does little to provide information about the true long-term
prophylactic effect of a treatment.
These issues suggest that the determination oflong -term effects after treatment for
migraine prophylaxis is difficult at the best . Fortunately some long-term treatment
information is available for up to 5 years on some migraine prophylactic treatments and
this information is reviewed below by treatment category.

Propranonol Long-Term Effects

Primary articles included in the present meta-analysis for Propranonol had
treatment lengths that ranged from 4-52 weeks. This is the amount of time that the
participants were taking Propranonol. Effect size did not significantly correlate with length
of treatment (r = -.272), indicating that participants achieved essentially the same
reduction in symptoms whether they took Propranonol for 1 month or 12 months . The
following authors reported that Propranonol effects were clearly maintained for up to 1
month after discontinuing the medication: Daholf (1987), Kangasniemi et al. (1983),
Nadelmann et al. (1986) , and Rao et al. (2000). Rao et al. reported that "successful
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treatment" effects are maintained for at least 5 months after discontinuation of daily
treatment with Propranonol.

Flunarizine Long-Term Effects

Primary articles included in the present meta-analysis for Flunarizine indicate that
there is a long-term treatment effect. As previously discussed, Flunarizine shows greater
effect sizes the longer it is taken . Studies included ranged in treatment length from 4-24
weeks. Regression analyses indicated that effect sizes were significantly larger when
treatment length was longer (R2 = 5.37, F =I5.06) . Only one study included in this metaanalysis reported follow-up data on migraine relief after discontinuation of treatment with
Flunarizine. Nuti et al. (1996) indicated that follow-up data showed that positive results
were maintained for 8.4 months± 4.0.

Divalproex Sodium Long-Term Effects

Primary articles included in the present meta-analysis for Divalproex Sodium
indicate that effect size does not vary with active treatment length. Treatment length did
not significantly correlate with effect size (r

=

-.223). Treatment lengths varied in the

present meta-analysis from 6-24 weeks. None of the articles included in the present metaanalysis provided information on maintenance of effect after discontinuation of active
treatment with Divalproex Sodium. Ghose and Niven (1998), in an article that was
disqualified from the present meta-analysis, reported that 60% of subjects maintain gains
for up 24 months with daily medication. In addition , Rothrock and Mendizable (2000),
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also not included in the present meta-analysis, reported that 60% of patients indicated that
gains made on Divalproex Sodium were maintained up to 2 months .

Nonpharmacological Long-Term Effects
Thermal biofeedback , relaxation treatments, and combination treatment outcome
studies show a different trend than pharmacological treatment studies. The
nonpharmacological treatments appear to focus on the effects of making treatments
shorter rather than longer. Thermal biofeedback and EMG biofeedback have both
experimented with brief therapeutic contacts that utilized at-home practice. The magnitude
of the treatment effect sizes do not statistically significantly change under these conditions .
For example, Blanchard et al. (1985b) reported that outcomes did not statistically
significantly differ whether they used brief biofeedback/relaxation training (2.6 hours of
therapeutic contact) or traditional training (11.6 hours of therapeutic contact) .
Articles that were included in the present meta-analysis on thermal biofeedback
ranged from 5-32 therapeutic contacts. Relaxation treatments range from 5-12 therapeutic
contacts. EMG biofeedback ranged from 5-12 therapeutic contacts. Relaxation treatments
and thermal biofeedback plus cognitive therapy ranged from 5-37 weeks and between 4-16
therapeutic contacts. Effect sizes did not vary by treatment length for thermal biofeedback
(r

=

.159) or relaxation therapy (r = .459). Some authors do address how longer term

active treatment affects treatment outcomes. Andrasik, Blanchard, Neff, and Rodichok
(1984) reported that up to 80% of subjects trained to use progressive muscle relaxation or
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progressive muscle relaxation, and thermal biofeedback maintained significant treatment
gains at 1 year when given monthly contacts for retraining.
Several reports regarding posttreatment outcomes are available. Many authors
report that the effects of thermal biofeedback, relaxation treatments, and EMO treatments
are effective for at least 4 weeks after discontinuation of treatment (e.g., Blanchard,
Andrisak , Neff, Arena, et al., 1982; Holroyd et al., 1995; Holroyd et al., 1988; Jurish et
al., 1983). Some have reported even longer term gains, Blanchard, Appelbaum, Nicholson
et al. (1990) rep011ed a 4-month maintenance of treatment gains for thermal biofeedback
treatment when the participant achieved an initial 50% reduction in frequency during initial
treatment. Daly et al. (1983) reported that participants who were given thermal
biofeedback or EMG biofeedback maintained gains for up to three months but that those
given relaxation training did not. A six year follow up conducted by Lispers and Ost
( 1990) indicates that treatment effects are largely maintained for up to 6 years for
participants treated with biofeedback (EMG or thermal). Similarly, Sorbi et al. (1989)
reported that participants who could be followed for 3 years maintained or increased
frequency reductions of migraine when they received relaxation training. Richardson and
McGrath (1989) reported positive 6-month outcome effects for participants who received
thermal biofeedback and cognitive therapy. They reported that mean treatment frequency
scores were statistically significantly lower than baseline at a 6-month follow-up.
However, Blanchard et al. (1978) reported that by 4 years those treated with thermal
biofeedback or relaxation training were approaching baseline frequencies of migraine
headaches.
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Summary

The effects of Jong-term treatment for migraine can be summarized as follows.
Once a reduction of symptoms is achieved via any of the above treatments an individual is
likely to maintain that reduction of symptoms as long as they are actively being treated.
Once the treatment is discontinued the effect may vary by treatment . Propranonol effects
may maintain for at least a month, Flunarizine effects may maintain for 8 months ,
Divalproex Sodium may maintain for up to 2 months, thermal biofeedback and EMG
biofeedback may maintain for 6 years , relaxation treatments may maintain for up to 3
years, and thermal biofeedback plus cognitive treatments may maintain for 6 months .
However, all of these results should be interpreted with caution due to methodological
pro blems inherent in the studies.

Practical Implications

The findings of the present meta-analysis do little to clarify which treatment should
be recommended. The results indicate that most of the treatments reviewed produce nearly
the same effect size. All effects (excluding those from EMG biofeedback treatments) are
considered moderate to large. Thus, individuals who choose from among Propranonol,
Flunarizine, Divalproex Sodium, thermal biofeedback, relaxation therapy, and thermal
biofeedback plus cognitive therapy for migraine prophylaxis are likely to see some
reduction of symptoms.
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As a result determining the treatment of choice must take into account factors
other than effectiveness rates . Ward (2000) suggested that the selection of treatment for
migraine prophylaxis should be made on the basis of comorbid disorders . If another
condition exists that can simultaneously be treated with one of the agents, then this
treatment should be selected first . Ward reported that some commonly found conditions
(and treating agents) that should be considered are hypertension (Propranonol) , mitral
valve prolapse (Propranonol) , anxiety (Propranonol) , bipolar disorder (Divalpoex
Sodium) , epilepsy (Divalproex Sodium), Raynauds disease (Flunarizine ). An excellent
decision tree that considers comorbid disorders and contraindications for migraine
prophylaxis pharmacological treatment appears in Adelman and Von Seggem (1995).
Ward (2000) did not mention the use of nonpharmacological treatments but the
same logic applies. Previous research shows that these nonpharmacological treatments
work well for conditions other than migraine prophylaxis. Researchers have documented
that thermal biofeedback and relaxation therapy are effective in treating anxiety
(Culpepper, 2002), depression (Setter & Kupper, 2002), and high blood pressure (Setter
& Kupper). Thermal biofeedback in particular has been noted to treat circulation issues in

Raynauds disease (Sappington & Fiorito, 1985 ). As can be seen, Ward's suggestion to
select via comorbid disorders narrowed the fields of treatments, but did not identify a
single best choice treatment.
Another consideration in choosing a treatment may be compliance. As previously
mentioned compliance with treatment regimes is a documented problem in migraine
prophylaxis (Mullemers et al., 1998). The above-researched techniques will not have the
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complete desired effect if the individual is unable to comply with treatment
recommendations. If compliance issues are of concern for an individual, then issues that
impact compliance should be considered when selecting the treatment of choice. One way
of selecting the best treatment may be choosing the one that requires the least time and
energy expenditure. Of the above treatments, Propranonol and Flunarizine are likely to be
adhered to with the least amount of problems (each treatment can be administered on a
once-a-day schedule). Given that Flunarizine is not available in the United States ,
Propranonol would be the treatment of choice. Divalproex Sodium requires greater
compliance because it may be administered up to three times a day and requires regular
laboratory exams for safety reasons. All nonpharmacological treatments require more time
investment from the treated individual. However, an advantage to using
nonpharmacological treatment is the ability of the clinician to monitor compliance. That is,
many treatments involve components with the individual participating in their treatment in
the presence of the clinician.
When selecting the treatment of choice patient preference cannot be ignored. The
side effects profiles, time commitments, and long-term effects vary widely between these
treatments. Individuals often have specific belief systems that influence their preferences
for treatment. Individuals needing migraine prophylactic treatment should be informed of
the options and included in the decision making about treatment of choice so they can be
active participants in their own health care (Capobianco et al., 1996). Individuals who are
involved in making their own treatment decisions are more likely to value the treatment
they have chosen and, thus, adhere better to treatment guidelines.
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Finally, cost considerations need to be addressed. Adehnan and Von Seggern
(1995) identified that Propranonol (the twice-a-day preparation) as the least expensive
treatment. However, the one-time-a-day preparation was almost four times as expensive.
Divalpoex Sodium weighed in at almost 12 times the cost of the twice-a-day Propranonol.
Estimates for Flunarizine are not available given that it is not legal to sell within the United
States. The above estimates include only medication costs. The cost of doctor visits,
laboratory work , and third-party fees are not estimated. So this is an estimate of only a
part of the costs associated with the pharmacological treatments. Osterhaus and
Townsend ( 1991) estimated at that time that other medical costs per year per patient for
migraine management included $281 for emergency room visits, $148 for clinic visits, and
$387 for hospitalizations, averaging an additional $68 a month for pharmacological
treatments.
Nonpharmacological treatments are initially expensive. Treatment per session
prices can average $80. If seen weekly, the cost per month could be $240 , where
Divalproex Sodium plus monthly medical expenses are estimated at $158 per month.
Attanasio, Andrasik, and Blanchard (1987) reported that there was little difference in the
cost effectiveness between nonpharmacological treatments. All nonpharmacological
treatments have similar costs associated with the initial training. Importantly , Blanchard,
Jaccard, Andrasik , Guarnieri, & Jurish (1985) report that nonpharmacological treatments
significantly reduced costs after termination of treatment due to long-term effects and
patient self-management. As previously mentioned, long-term studies evaluating the
effects of nonpharmacological treatment effects indicated that reduced frequency of
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migraine is maintained up to 6 years (Lisspers & Ost, 1990). Pharmacological treatments
have very little support as to having a lasting treatment effect beyond a few months after
the active treatment phase. This suggests the costs associated with nonpharmacological
treatments are one-time costs where pharmacological costs are ongoing. Blanchard,
Jaccard, et al. (1985) reported that medical costs associated with treating headaches were
approximately $1,000 per year prior to nonpharmacological treatment and approximately
$50 per year following treatment (costs include medical costs and lost productivity). The
long term effects after treatment is discontinued indicate that nonpharmacological
treatments may be more cost effective than pharmacological treatments in the long nm.
In sum, a variety of factors influence treatment choice for migraine prophylaxis.
There is no single best choice for all individuals. Comorbid disorders , cost, and
compliance are just a few of the considerations in making the choice. However , the
current meta-analysis suggests that once the choice is made, if compliance is high, the
treatment is more likely than placebo to reduce frequency of headaches.

Limitations

The current findings are limited in several ways. First, these findings are directly
reliant on the quality and accuracy of the findings in the primary research. Second, the
combination of these two major bodies of research has resulted in the mixing of some
groups that may not be compatible. Finally, significant problems exist in the primary
literature for nonpharmacological treatments that limit their findings. Each of these
limitations are discussed below.
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Quality of Primary Research
These findings cannot outstretch the initial accuracy of the articles on which they
are based. The current meta-analysis attempted to address this issue through the use of
quality ratings. However, it should be noted that the quality scores used in this metaanalysis only address a few factors that could compromise outcome validity and reliability.
Thus, other serious threats or flaws may exist in the primary research that would challenge
the findings of this meta-analysis. The present meta-analysis supports the findings reported
by other meta-analytic studies (Duke University and The Center for Clinical Health and
Policy, 1999a, 1999b; Holroyd & Penzien; 1990). Nevertheless, all of these meta-analyses
have been based on the same primary research literature and may be subject to the same
primary flaws.

Summing Data
Subjecting the two bodies of research (pharmacological and nonpharmacological)
to the same standards and coding methods revealed several differences between the two
literature bases that may limit these findings. There are several procedural and
nomenclature differences between the two groups that may cause the outcome findings to
be limited. For example, the term ''vascular headache" is one commonly used in the
behavioral research. This term is defined as some form of migraine (mixed, classic, or
common). Researchers in the behavioral area often report results for the vascular headache
subjects as a group. The pharmacological research does not typically use mixed groups.
They tend to select subjects who have very specific migraine symptoms and then report
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results in two migraine categories (common or classic). The research included in this
meta-analysis for pharmacological treatments rarely included mixed headache patients.
However, subjects with transformed headache (a condition where individuals with
migraine headaches begin to have daily tension headaches intermixed with migraines due
to medication/reinforcement issues) are included in some pharmacological studies.
Subjects with transformed headache are not addressed in the nonpharmacological
research. This meta-analysis combines this diverse information into single summary effect
sizes for migraine headache treatments. In the process of summing these two diverse
bodies of literature some specific information may have been lost. Thus, the comparison of
the outcome of the treatments is limited to broad generalizations.

Problems in the Nonpharmacological Literature
The :findingsfor nonpharmacological treatments are significantly limited by (a) the
lack of studies that use an appropriate control or attention placebo group, and (b) an
overreliance on the percent improved score. The paucity of published controlled studies
on nonpharmacological treatments is not from the lack of trying. Rather, studies designed
as controlled trials have often selected attention placebo conditions that later demonstrate
an active effect. Researchers have attempted to use relaxation (Lacroix et al., 1983),
pseudo-meditation (Blanchard, Appelbaum, Radnitz, et al.. 1990), hypnosis (Reich, 1989),
false biofeedback (Reading, 1984), home biofeedback (Blanchard et al., l 985a), and
contact with a therapist by phone (Richardson & McGraph, 1989) as attention placebos.
However, each of these groups has shown similar effects to the active treatment group.
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The only control groups that appeared to consistently not have big treatment gains were
wait list groups. This phenomenon resulted in markedly fewer controlled studies that were
available for systematic review for nonpharmacological treatment than for
pharmacological treatments.
The second limiting factor found in the existing literature on nonpharmacological
treatments was the overreliance on the percent improved score. The percent improved
score was the individual improvement scores average for the group of treated individuals.
For example, authors may report that those in the thermal biofeedback group had a
percent improved score of 48%. Many authors in the nonpharmacological migraine
treatment area report this score as their primary outcome index. When this is the case ,
individual data are lost because it is impossible to tell if the individuals in the treatment
group went from 4 headaches a month to 2 headaches a month , or from 10 headaches a
month to 5 headaches a month. Both are significant changes but have different meanings.

In addition , it is not standard to report the percent improved score with variance scores.
Therefore , it is impossible to tell if most subjects in the study were near the reported
percent improved score or if there was a great deal of deviation. Without standard
reporting of variance these scores become less meaningful.
The combination of the lack of a true control condition and inadequate statistical
reporting (primarily due to the overuse of the percent improved score) resulted in a large
number of primary research articles that could not be quantitatively compared. These
studies did not lend themselves to standardization via quantitative methods and thus had to
be disqualified from the current meta-analysis. As a result, this meta-analysis is based on
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only a :fraction of primary articles available on nonpharmacological treatments. Therefore,
the conclusions drawn from these findings may be limited by being based on only a small
portion of the available research findings.

Suggestions for Future Research

Continued research in the area of migraine prophylaxis is recommended, however,
prior to beginning new trials researchers need to recognize what is not needed in this area.
Research on why biofeedback treatments are superior to relaxation treatments for
migraine prophylaxis is no longer needed because the current body of literature shows that
biofeedback is not superior to relaxation treatments. Though not directly addressed in this
meta-analysis there is also no current need to establish the ideal body temperature change
that a person needs to obtain for biofeedback to be effective. Results clearly ind.icate that
classic and common migraine patients cannot change their body temperature as readily as
other type of subjects; however, ability to reach certain temperature changes does not
correlate with the decrease of headache frequency (Werbach & Sandweiss, 1978).
Another course of action that no longer seems warranted is research on combination
therapies that do not use two empirically validated treatments. There is not a valid
rationale for throwing treatments together that have not been established as effective by
themselves (e.g., EMG biofeedback plus hypnosis with autogenic training). Finally, the
role of Propranolol is clearly established in migraine prophylaxis. There is little need for
continued controlled trials to replicate this finding.
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These areas aside, the findings of present meta-analysis indicate future research is
needed in the area of migraine prophylaxis. More research is needed on (a) controlled
trials on nonpharmacological treatments, (b) the effect of combining empirically supported
treatments from the two categories (nonpharmacological and pharmacological) , and (c)
the development of a comprehensive theory on migraine that combines findings from
different fields. Each of these suggestions are discussed below.
First, the value of nonpharmacological prophylactic treatments (other than thermal
biofeedback) needs to be clearly established. This can only be done through clearly
controlled basic research studies that replicate outcome findings. The lack of basic
research on commonly accepted techniques for nonpharmacological treatments is
alarming. Many authors have shifted on to investigating correlates of outcomes for
relaxation and cognitive techniques, citing as part of their study rational that the benefits
of these treatments are clearly documented by other authors (e.g., Hart, 1984). This is not
a valid rationale for all nonpharmacological treatments. As shown in the current metaanalysis, there is a large body of research regarding the use of these techniques for
migraine prophylaxis ; however, very little of the research works to establish that the basic
effects of these treatments are greater than placebo/control group gains.
A related issue is the need for the identification of an appropriate attention placebo
condition for migraine prophylaxis. The definition of attention placebo as it relates to
behavioral interventions has often been debated. Definitions for attention placebo as it
applies to nonpharmacological treatments include: (a) a treatment or procedure that has no
specific effect, but that can be presumed to have an effect (Shapiro & Morris , 1978), (b) a
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substitute for a genuine treatment (Senger, 1987), and (c) nonspecific treatment facters
that encourage hope, learning, sharing, emotional arousal, and mastery, but do not provide
any specific effect (Fish, 1973). The variety of definitions available for attention placebo
stems large]y from the attempt to apply a medical term to psychotherapy. The term
placebo in medical arena's refers to the procedure of giving an inactive substance in the
place of a chemically active substance to rule out interpersonal and expectation factors as
a cause of outcome (Senger). This, obviously, is a difficult concept to apply to
nonpharmacological interventions that rely on interpersonal factors for treatment. This has
led some authors to suggest that effects of psychological and behavioral treatments are
nothing more than extensive placebo effects (e.g., Patterson, 1967). Thus, it may be
argued that the observed effects for nonpharmacological prophylactic treatments for
migraine are merely attention placebo effects. A strong argument against this comes from
Mathew ( 1981), who reported multi-arm treatment findings. He suggested that thermal
biofeedback and Propranolol have similar effectiveness rates, but that both are better than
placebo. If thermal biofeedback were just a strong placebo effect, one would expect the
efficacy rates to be lower than Propranolol and more equivalent to placebo results.
However, this is not the case .
Thus, it is likely that thermal biofeedback, relaxation therapy, and combined
therapies have a specific effect that causes the reduction of migraine frequency. If this is
the case, this effect needs to be demonstrated above and beyond hope, expectation, and
interpersonal factors through controlled studies that employ attention placebo groups.
In the pharmacological migraine prophylaxis literature, the placebo effect has been
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demonstrated to account for at least 35% improvement in migraine frequency (Couch,
1987). If this same approximate rate can be applied to nonpharmacological treatments,
then an attention placebo could be defined as a treatment that does not include specific
treatment factors that causes approximately 35% improvement but does not equal total
treatment effect of the active treatment. The present study will use this definition of
attention placebo.
The difference between attention placebo groups and active treatment groups
needs to be established in the nonpharmacological literature. It is apparent in the existing
body of literature on nonpharmacological migraine prophylaxis that any attention placebo
condition that involves regular visits, sitting alone in a treatment room, machines that have
face validity, or guided relaxation treatment at home , will show a treatment effect and,
therefore, not be an attention placebo. This suggests that the nonpharmacological
treatments have a common active component that has yet to be explained. It is possible
that the act of routinely engaging in a quieting or calming activity or that the education
provided when the treatments are undertaken, or that providing a rationale to participants
may be the common active feature. Many authors have documented the fact that the
nonpharmacological treatments are better than wait list controls (e.g., Blanchard,
Appelbaum, Nicholson, et al., 1990; Blanchard, Nicholson, Radnitz, et al., 1991; Gauthier,
et al., 1985). It can then be assumed that the nonpharmacological treatments are
providing treatment beyond time and daily self- monitoring, but how they are providing
this treatment is still uncertain. An important part of discovering the active components in
nonpharmacological treatment will be identifying an attention placebo that does not elicit
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the same treatment effect. The studies included in the current meta-analysis in the EMG
biofeedback plus thermal biofeedback plus relaxation treatment condition may offer some
guidance in this area. This treatment category included three primary articles that used
control groups that document approximately 20-30% gains. These gains are similar to
those often reported for placebo (i.e., 35%). Two of the studies included control groups
who were told to go home and relax without specific instruction (McGrady et al., 1994;
Waquier et al., 1995) . The fact, that the authors were able to document treatment effects
for EMG biofeedback plus thermal biofeedback plus relaxation above and beyond their
control group is promising. It should be noted that the net result in the current metaanalysis of using control conditions rather than a wait list group was a lower summary
effect size for this treatment (In (OR) = 1.11) . This may suggest that when a true
attention placebo for nonpharmacological migraine prophylactic treatment outcome
studies is found, the noted treatment effect sizes for the nonpharmacological treatments
may be reduced ( due to the methods of calculating effect sizes)

It appears that adding treatments within a category (nonpharmacological or
pharmacological) does little to improve the efficacy of the treatment. This is most clearly
see in the nonpharmacological treatments. Results show that most treatments in the
nonpharmacological area have the same effect even if they are combined (e.g., thermal
biofeedback and thermal biofeedback plus relaxation plus cognitive therapy have nearly
the same effect sizes). However, future research in the area of cross-category combination
treatment is needed. Taking a treatment from the nonpharmacological category and one
from the pharmacological category that are both empirically supported and combining
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them is a relatively unexplored area . There are currently only two articles that examine the
effects of one of these combinations; thermal biofeedback plus Propranonol (Holroyd et
al., 1995; Mathew, 1981) Both studies reported promising results. Holroyd, France, et al.
reported that the use of a combined thermal biofeedback and Propranonol approach was
significantly better than using biofeedback alone. Mathew (1981) reported that thermal
biofeedback plus Propranonol was superior to Propranonol alone, or thermal biofeedback
alone . In addition, Mathew reported that biofeedback plus Propranonol was superior for
migraine prophylaxis to all seven treatments examined in the same article (control,
Propranonol , Amitriptyline, thermal biofeedback , Propranonol plus Amitriptyline,
Amitriptyline plus thermal biofeedback, and Propranonol plus Amitriptyline plus thermal
biofeedback) . However , the author notes that these results are for migraine headache only
and that results for mixed headache differ. It is interesting to note that both articles are
relatively old by research standards and that little has been done to follow-up on their
findings.
A primary need in the area of migraine research is a new guiding theory that takes
into account the available research findings. Much of the research on migraine prophylaxis
appears haphazard and undirected. This may be due to the lack of a unifying theory about
the course of migraines and bow variables interact with one another. There seems to be
very little work being published that attempts to integrate findings on migraine from
various research fields. Pharmacological, nonpharmacological, genetic, and biological
researchers are reporting some perplexing findings that need to be addressed. For
example, why do false biofeedback and true biofeedback not statistically significantly differ
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in outcome for migraine prophylaxis when they both are statistically better than wait list
groups? Or why does Propranonol seem to be one of the few beta-blockers that actually
works as a migraine prophylactic? And why do Propranonol, thermal biofeedback, or
practicing home relaxation seem to all have similar effect?
The development of a theoretical hypothesis that synthesizes these and many other
results could direct researchers toward potentially fruitful areas of research and away from
repeated problems of the past. The unification of many fields through theory would allow
researchers to work with each other. Potentially, a concrete theory could help eliminate
the irrelevant and redundant research that is present in this body of literature (e.g., 30
years of research that uses relaxation as a control group or repeated studies on the brand
of machine needed to give biofeedback when a basic thermometer seems to work just as
well).
In sum, research on migraine and migraine prophylaxis needs to be theory driven.
Ideally, the theory would address the pathogenesis, genetic research, psychological
contributions, common pathways, and treatment of migraine. The theory would address
the results of the present meta-analysis and the results of other meta-analytic studies that
indicate treatments have similar effect sizes and none of these effect sizes are as high as
one would hope after 30 years of research. In addition, the theory would suggest specific
hypothesis that could be tested in various fields. Such a unifying theory seems crucial to
reaching a better understanding of the complexity of migraine headaches.
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Appendix A: Pharmacological Agents' Names

Table Al

Pharmacological Agents' Names
Category

Brand name

Generic name

Chemical nan1e

Beta-adrenergic
blocker

Inderal®

Propranonol

*(Isopropylanuno )-3-(1-n
aphthyloxy)-2-propanol
hydrochloride.

Calcium channel
blocker

Sibelium ®

Flunarizine

*(4-fluorophenyl)-Methyl
-4-(3-phenyl2-propenyl)
*piperazinedihydrochloride.

Anti-convulsant

Depakote ®

Divalproex
Sodium

*sodium hydrogen
(2-propylpentanoate ).
*valproic acid
*sodium valproate

Appendix B : Summary of Reviews

Table Bl

Summary of Reviews

Authors (date)
Blanchard, Andrasik,
Ahles, Teders, &
O'Keefe (1980)

Type of
headache
migraine

Types of
treatment
biofeedback,
relaxation,
bio/relax.

Number of
studies
analyzed

47

Quantitative
(yes/no)
yes

Type of change
score used
pre-post change
scores

Other variables
considered
gender,
age,
quality,
duration of
treatment.

Major findings
All three
treatments show
similar
effectiveness
rates .
Outcome does not
vary by gender or
age
Inconclusive on
duration of
treatment.

(table continues)
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N

Authors (date)
Bogaards & ter Kuile
(1994)

Type of
headache
tension
headache

Types of
treatment
EMO
Biofeedback,
Relaxation,
Bio/relax,
Cognitive
Therapy.
Pharmacological
(amitriptyline,
diazepam,
ibuprofen,
asprin,
acetaminophen,
naproxensodiwn,
clomipramine,
doxepin,
trzanidine)
Placebo,
Control.

Nwnber of
studies
analyzed

78

Quantitative
(yes/no)
yes

Type of change
score used

Other variables
considered

pre-post
treatment scores

treatment setting,
duration of
treatment, therapist
training,
age,
duration of
headache,
gender,
method of subject
recruitment,
nwnber of subjects,
drop outs,
outcome measure,
diagnostic criteria,
year of publication,
internal validity.

Major findings
All nonpharmacological
treatments are
superior to
pharmacological
treatments for
tension headache
(when
pharmacological
treatments are
pooled).
Outcomes vary by
type of outcome
measure used
(headache diary
versus other
methods.
Studies that
examine short
duration
treatments result
in higher
percentages of
improvement.
Age is related to
poor outcome.
Gender and
method of
recruitment are
not related to
outcome.

(table continues)
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Authors (date)
Compas, Haag, Keefe,
Leintenberg, & Williams
(1998)

Type of
headache
migraine

Types of
treatment
Cognitive
therapy,
Cog-beh
therapy,
biofeedback,
relaxation.

Number of
studies
analyzed
21

Quantitative
(yes/no)
no

Type of change
score used
pre- post
improvement

Other variables
considered
none

· Major findings
All biofeedback
and relaxation
treatments have
similar effect
rates.
There is limited
·evidence for
Cognitive
therapies, but
what is available
appears
promising.

Duke University & The
Center for Clinical
Health Policy Research
(1999a)

migraine

Relaxation
therapy,
thermal
biofeedback,
EMG
biofeedback,
cognitivebehavioral
therapy,
acupuncture,
TENS, spinal
manipul-ation,
hyperbaric
oxygen.

29

yes

Standard-ed
effect
sizes
percent
improved

none

Thermal
biofeedback plus
relaxation
therapy,
relaxation
training, and
EMG biofeedback
are al modestly
effective in
treating migraine.

(table continues)
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Authors (date)

Type of
headache

Duke University & The
Center for Clinical
Health Policy Research
(1999a)

migraine

Flor, Fydrich, & Turk
(1992)

back pain

Types of
treatment

Number of
studies
analyzed

(Category-see
detailed list at
the end of the
table)
alpha-2agonsits,
anitconvulsants, antidepressants,
beta-blockers,
calcium
antagonists,
ergots,
NSAIDS,
hormonal
treatments, and
seritonin-ergic
drugs.

258

no headache
treatments
examined

65

Quantitative
(yes/no)
yes

Type of change
score used
Standardized
effect sizes,

Other variables
considered
none

Propranolol,
timinolol,
divalproex
sodium,
amitriptyline,
flunarizine, and
pizotifen all have
effect sizes
between .52 and
.93. Participant
drop outs are a
major issue in
pharmacological
research.

age,
gender,
pain duration,
% working,
% married,
years in school,
litigation,
compensation,
surgery,
long/short term.

Outcome varies
by age, marital
status, education
'level, SES,
employment stats,
compensation and
medication use.

Odds ratios

yes

Standardized
effect sizes

Major findings

(table continues)
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Authors (date)
Holroyd & Penzien
(1985)

Type of
headache
tension and
client
variables

Types of
treatment
EMG
Biofeedback,
Relaxation,
Combo
treatment,
no treatment,

Number of
studies
analyzed

37

Quantitative
(yes/no)
yes

Type of change
score used
Pre-post change
scores (only
from studies
using headache
diaries)

Other variables
considered
# of subjects,
dropout,
gender,
age,
source of client,
duration of
treatment,
transfer training,
assignment to
groups,
internal validity,
diagnostic criteria.

Major findings
Outcome does not
vary by research
design .
Outcome varies
by age, year of
publication,
gender, and
dropout rate.
All treatments
have similar
effectiveness
rates.

(table continues)
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Authors (date)
Holroyd & Penzien
(1990)

Type of
headache
migraine

Types of
treatment
Propranonol,
bio/relax ,
no treatment ,
placebo.

Number of
studies
analyzed

60

Quantitative
(yes/no)
yes

Type of change
score used
headache index

Other variables
considered
Outcome measure .

pre-post scores

Major findings

43%
improvement for
both active
treatments.
Treatment effects
vary by outcome
measure .

Holroyd & Penzien
(1990)

migraine

Propranonol,
relaxation /
biofeedback ,
placebo .

73

yes

headache index
pre-post
improvement
score

number of subjects ,
gender,
age,
outcome measure,
dropout rate,
migraine diagnosis,
Propranonol dose,
dropout due to side
effects,
blind to condition,
# ofbio sessions,
transfer training.

Similar
improvement
rates for
biofeedback/relax
ation training and
Propranonol.
Results vary by
type of outcome
measure (daily
recording versus
global estimates).

(table continues)
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Authors (date)
Holroyd, Penzien, &
Cordingley (1991)

Type of
headache
migraine

Types of
treatment
Propranonol.

Number of
studies
analyzed

53

Quantitative
(yes/no)
yes

Type of change
score used
pre-post scores,
placebotreatment
change score

Other variables
considered

Major findings

# of subjects,
age,
migraine diagnosis,
chronicity ,
dropout rate,
drop out due to side
effects,
dose,
blind to condition.

Conservative
estimates of
Propranonol
treatment effects
indicate a 44%
reduction in
frequency,
duration, and
intensity of
migraine
headache.
Dose issues do
not effect
outcome.
Type of outcome
measure do effect
treatment
outcome
(headache diary
versus global
measurements)

Lander (1980)

general pain

No headache
treatments
considered.

42

no

none

patient variables,
differences in
sample, selection,
gender,
SES,
age,
duration of pain

Research on pain
management is
poor due to
methodological
flaws and a
failure to include
the referenced
variables.

(table continues)
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00

Authors (date)
Onghena & Van
Houdenhove (1992)

Malone & Strube (1988)

Type of
headache
tension
headache,
migraine,
chronic
pain.

nonChronic
pain

Types of
treatment

Number of
studies
analyzed

amitriptyline,
phenelzine,
irniprarnine,
doxepin,
dibenzepine,
clomipramine,
femoxetine,
dothiepin,
mianserin,
trazodone,

39

atogenic
biofeedback,
cognitive,
hypnosis,
no treatment,
operant,
pill placebo ,
relaxation,
wait list.

109

Quantitative
(yes/no)
yes

yes

Type of change
score used
Standardized
effect size

standardized
effect size,
percentage
improved (prepost)

Other variables
considered
dosage level,
depression
diagnosis,
# of patients,
gender,
mean age,
mean duration of
pain,
quality,
use of analgesics.
type of pain
(back, neck, cancer,
dental, iatrogenic,
join, migraine ,
mixed group, mixed
headache, tension
headache, other) .

Major findings
Antidepressant
medications
induce an
analgesic effect.
The effect
decreases pain in
all of the pain
conditions tested .

Outcomes vary by
how researchers
calculate change
(effect size or %
improved) .
Effect size is
more sensitive .
Treatments are
uniform in
outcome across
pain categories.

(table continues)
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Treatments examined in Duke University and the Center for Clinical Health Policy Research.
Alpha-2-agonistsis
clonidine, guanfacine.

Anticonvulsants
divalproex sodium, carbamazepine, clonazepam, gabapentin.
Antidepressants
amitriptyline, clomipramine, femoxetine, fluoxetine, fluvoxamine, mianserin, opipramol.
Beta-blockers
propranolol, metoprolol acebutolol, alprenolol, atenolol, bisoprolol, nadolol, oxprenolol, pindolol, practolol, timolol.
Calcium antagonists
cyclandelate, flunarizine, nicardipine, nifedipine, nimodipine, verapamil.
Ergots
dihydroergotamine, dihydroergokrptine, egrotamine, Cafergot

Methysergide; nonsteroidal anti-inflammatory drugs (NSAIDS)
aspirin, fenoprefen, flurbiprofen, indobufen, idomethacin, ketoprefen, lomoxicam, mefamic acid, naproxen, naproexn sodium,
tolfenamic acid.
Other Serotoninergic Drugs
pizotifen, lisuride, oxitriptan, iprazochrome, tropisetron.
Other Treatments
hormonal preparations and feverfew.

.....

v,

0
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Appendix C: Excluded Articles
Table C l
Propranolol Excluded Articles
Authors (date)

Reason for exclusion

Al Qassab & Findley, 1992

Insufficient data

Baldrati et al., 1983

Insufficient data

Behan & Reid, 1980

Insufficient data

Bordini, Arruda, Ciciarelli, & Speciali, 1997

Insufficient data

Carroll, Reidy, Savundra, Cleave, & McAinsh, 1990

Insufficient data

Cortelli et al., 1985

Insufficient data

Diamond, Kudrow, Stevens, & Shapiro, 1982

Insufficient data

Diener et al., 2002

Insufficient data

Gawel, Kreeft, Nelson, Simard, & Arnott, 1992

Insufficient data

Gerber, Diener, Scholz, & Niederberger, 1991

Insufficient data

Gerber et al., 1995

Insufficient data

Holroyd, Penzien, Rokicki, & Cordingley, 1992

Brief report-insufficient data

Kass & Nestvold, 1980

Insufficient data

Leahey, Neill, Varma & Shanks, 1980

Results on blood pressure

Malvea, Gwon, & Graham, 1973

Insufficient data

Olerud, Gustavsson, & Furberg, 1986

Insufficient data-no control
group

Olsson et al., 1984

Insufficient data-no control
group

Palferman, Gibberd, & Simmonds, 1983

Insufficient data
(table continues)
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Authors (date)

Reason for exclusion

Pascaul, Polo, & Berciano, 1989

Insufficient data

Raskin & Schwartz, 1980

Retrospective study

Scholz, Gerber, Billie, Niederberger, & Fahrner,
1987

Report results for plasma levels
only

Shimell, Fritz, & Levien, 1989

Insufficient data

Solomon, 1986

Abstract-unusable statistics

Stensrud & Sjaastad, 1980a

Insufficient data

Stensrud & Sjaastad, 1980b

Duplicate of above

Sudilovsky et al., 1987

Cost effectiveness study

Wobeer, Wober-Biingoi, Koch, & Wessely, 1991

Long term results after
discontinuation of treatment.
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Table C2

Flunarizine Excluded Articles
Authors (date)

Reason for exclusion

Amery, 1983

Reviews others data

Amery et al., 1981

Reviews pharmacology

Angoli et al., 1991

Comparison-provided
insufficient data

Andersson, 1985

Abstract, insufficient data

Baker, 1987

Abstract, insufficient data

Bassi, Brunati, Rapuzzi, Alberti, & Mangoni, 1992

Insufficient data

Bonuso et al., 1986

Migraines induced

Centonze et al., 1983

Insufficient data

Centonze, Magrone, & Vino, 1990

Insufficient data

Cerbo et al., 1986

Insufficient data

D'Amato, D'Amato , Alfano, Giordano, & Marmo,
1990

Insufficient data

Diamond & Schenbaurn, 1983

Insufficient data

Germain & Neuron, 1990

Insufficient data

Grotemeyer, Schlake, & Husstedt,.1987

Insufficient data

Grotemeyer, Schlake, & Husstedt, 1989

Insufficient data

Hansen, Sorensen, & Olesen, 1989

Insufficient data

Holmes, Brogeden, Heel, Speight, & Avery, 1984

Review

Leandri, Parodi, Bacigalupo, & Farinini, 1985

Data artificially dichotomized

Louis, 1987

Insufficient data

Louis and Spierings, 1982

Insufficient data

(table continues)
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Authors (date)

Reason for exclusion

Martinez-Lage, 1988

Included large numbers of
dhildren

Mendenopoulos, Manafi, Logothetis, &
Bostantjopoulou, 1985

Duplicate ofMentenopoulos,
Manafi, Logothetis, &
Bostantjopoulou, 1985

Nappi et al., 1987

Comparisonprovides insufficient data

Pfaffenrath, Oestreich, & Haase, 1990

Focus on acute treatment

Schmidt & Oestreich, 1991

Clinical case review

Sorenson and the Danish Migraine Study Group, 1989

Comparisonprovides insufficient data

Soyka & Oestreich, 1987

Insufficient data

Soyka, Taneri, Oestreich, & Schmidt, 1988

Focus on acute treatment

Spierings & Messinger, 1988

Reviews others data

Sterdo et al., 1986

Comparisonprovides insufficient data

Wauquier, Ashton, & Marranes, 1985

Focused on animal models
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Table C3

Excluded Divalpoex Sodium Articles
Authors (dates)

Reason for exclusion

Hering & Kuritzky, 1992

Insufficient data

Klapper, 1997

Insufficient data

Mathew & Ali, 1991

Insufficient data

Mitsikostas & Polychronidis, 1997

Insufficient data

Silberstein & Collins, 1999

Insufficient data

Sorensen, 1988

Insufficient data
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Table C4
Nonpharmacologica/ Excluded Studies

Authors (dates)

Reason for exclusion

Alder & Alder, 1976

Inappropriate design

Anderson, Basker, & Dalton, 1975

Treatment not included

Andrasik, Blanchard, et al., 1984

Insufficient data

Andrasik, Pallmeyer, Blanchard, & Attanasio,
1984

Not outcome based

Andreychuk & Skriver, 1975

Insufficient data

Billings, Thomas, Rapp, Reyes, & Leith, 1984

Retrospective

Blanchard, 1987

Chronic headache

Blanchard, Andrasik, Evans, et al., 1985c

Insufficient data

Blanchard, Andrasik, Neff, Arena, et al., 1982

Inappropriate design

Blanchard, Andrasik, Neff, & Appelbaum, 1985

Inappropriate design

Blanchard, Andrasik, Neff, Teders, et al., 1982

Inappropriate design

Blanchard et al., 1987

Follow-up

Blanchard, Jaccard, Andrasik, Guarnieri, &
Jurish, 1985

Focus on expenses

Brown, 1984

Treatment not included

Cohen, McArthur, & Rickles, 1980

Insufficient data

Daly, Donn, Galliher, & Zimmerman, 983

Insufficient data

Diamond & Montrose, 1983

Retrospective

Fahrion, 1977

Insufficient data

Feuerstein & Adams, 1977

Single subject

French, Gauthier, Roberge, Bouchard, & Nowen,
1997

Insufficient data
(table continues)
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Reason for exclusion

Authors (dates)
Friedman & Taub, 1984

Insufficient data

Ford , Stroebel, Strong, & Szarek, 1983

Insufficient data

Gainer, 1978

Single subject

Gallagher & Warner, 1984

Insufficient data

Gamble & Elder, 1983

Insufficient data

Gauthier, Bois, Allaire, & Drolet , 1981

Insufficient data

Gauthier & Carrier, 1991

Follow-up

Gauthier, Doyon, Lacroix , & Drolet , 1983

Treatment not included

Gauthier , Fradet , & Roberge , 1988

Insufficient data

Gauthier, Ivers, & Carrier, 1996

Review

Hart, 1984

Insufficient data

Holroyd et al., 1989

Used only successfully treated

Howard , Reardon , & Tosi, 1982

Single subject

Ilacqua , 1994

Insufficient datano frequency data

Janssen & Neutgens , 1986

Insufficient data

Kabela, Blanchard, Appelbaum, & Nicholson
(1989)

Too few migraine subjects

Kewrnan & Roberts , 1980)

Insufficient data

Lacroix et al., 1983

Insufficient data

Lisspers & Ost, 1990

Follow-up

Mizener, Thomas, & Billings, 1988

Insufficient datano frequency data

Morrill & Blanchard, 1989

Insufficient datafocus on temperature

Nicholson & Blanchard, 1993

Too few migraine subjects

(table continues)
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Authors (dates)

Reason for exclusion

Olson, 1988

Follow-up on mixed headache

Reading, 1984

Insufficient data

Reich, 1989

Insufficient data

Sargent, Walters, & Green, 1973

Insufficient data

Smith, 1987

Insufficient data

Sorbi & Tellegen, 1984

Insufficient data

Sorbi & Tellegen, 1986

Treatment not included

Sovak, Kunzel, Stembach, & Dalessio, 1981

Insufficient data

Turin & Johnson, 1975

Too few subjects

Werbach & Sandweiss, 1978

Insufficient data
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Appendix D: Data Collection Materials

Table Dl

Coding Sheet
Study ID#
Headache type
!=migraine
2=mixed
}=vascular
treatment type
l =pharrn
2=nonpharm
subgroup
l =Propranonol
2=flunarizine
3=Divalproex Sodium
4=TBF
5=Relaxation
6=EMG
7=Cog therapies
% sample female

Type of headache record
( I =daily diary
2=client estimation
3=researcher estimate).
Treatment length in weeks
Comparitive group
!=placebo
2=control
}=baseline-control
4=baseline comparison
Study type
!=parallel
2=crossover
Year of study

(table continues)
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Study ID#

# of months between
treatment and follow-up
# of days drug wash out
period
# of sessions 2

Total mortality rate
Data type
I =continuous
2=binary
Stats-mean
sd, s, ci
t, F, Z, r

pre-post
within
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Table D2

·Data Page

Sp=
nl =
sl(sqr)=
Sp=

2

+ (n2- l)s2 2
nl + n2- 2

(nl- l)sl

n2=
s2(sqr)=

~~~~~~~~~~~~~

Expenmenta I
N

·-

Mean
F
T
P(exact)
paired T
pre
post

Binary
%Success

contro

-
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Appendix E: Quality of Study Rating Sheets

Question
1

la

2
2a

3

Was the study described as randomized (this
includes the use of words such as randomly,
random and randomization)
If the method of generating the sequences of
randomization was described, was it adequate
(table of random numbers, computer-generated,
coin tossing etc.) or Inadequate (allocated
alternately, according to date of birth , hospital
number, etc)

Was the study described as double blind?
If the method of blinding was described, was it
adequate (identical placebo , active placebo,
dummy etc) or inadequate (comparison of tablet
vs. injection with no double dummy)

Was there a description of withdrawals and
dropouts

Response

Score

yes

1

no

0

Not described

0

Adequate

1

Inadequate

-1

Yes
No

1

0

Not Described
Adequate

0

Inadequate

-1

Yes
No

1
0

1

Score=
Note. For sections la and 2a a study automatically receives a zero in these sections if the
previous section (lor 2) is a zero. The scores of(-1) are only used when the study scored
a (1) on the previous section. For example, a study that specifically states that it is
randomized but then states it used alternate allocation would receive a score of"l" in
section (1) and a score of a "-1" section (la). Therefore, no study can receive a score of
less than zero. Alternatively, a study that specifically states that it is a double blind study
but does not describe how double blinding was achieved would receive a score of"l" in
section (2) and a score of" O" in section (2a).

Figure El . Quality of study instrument (Jadad et al., 1996).
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NECESSARY CONDITIONS

Measurement of Headaches
Type of Control

1 point

O points

Journal/Likert Scale
_ _ Placebo/Comparison

__

Self Report
Baseline

OTHER CONDITIONS
Yes= l

No=O

Cross-Over Design
Run-in/Wash Out Period
Baseline/follow-up
Multiple Setting
Compared to another
Active tx.
Other Meds Controlled
Compliance Measured/
Homepractice
3=Great = All Necessary conditions and 3 other
2=Good = at least 1 of Necessary conditions and 3 other or 2 Necessary and 2 other
1=Okay = no Necessary conditions or 1 Necessary condition and less than 3 other
Nee. Cond =
+
=

Figure E2. Headache literature quality rating .
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Appendix F: Formulas Used in Calculations of Effect Size

All calculations were performed with the aide of Meta-Stat ® a statistical software
program developed by Rudner, Glass, Evart, and Emery (2000).

Calculating an unbiased standardized mean difference (d)
Equation 1

g

= X exp- X cont/ SDpooied

Equation 2
d= g(l-(3/4m-1))

Example 1
So, if an article presents and experimental mean of3.69 (N

=

80)

and a control mean of2.54 (N = 80). A pooled standard deviation
of 3.65. Results are as follows,
g = 3.69 - 2.54/3.65

=

d = .31 (1-(3/4(158)-1)
d = .31 (1-(3/631)

d = .308

.31
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Calculating an effect size from Parametric Gain Scores
Equation 3
Xepost

-

d=-----

X epre

X

con tpost -

X con tpr e

O contp re

O exp re

Example 2
So if the article presents experimental treatment group data as
Pre Mean= 4.12, SD = 3.7, Post Mean 1.57, SD= 1.35
and control group data as Pre Mean = 3.4, SD= 2.98, Post Mean 2.72, SD
= 1.78
The calculation would be as follows
d = (4.12-1.57)/3.7 - (3.4-2.72)/3.4
d = 2.55/3 .7 - .68/3.4
d = .689 - .2
d = .489

Calculating an effect size as a paired comparison t-test
Equation4

d

--fii

= D--

t

Where D is the mean difference between the observed pairs.
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Example 3
So, for an article that presents a paired t score of2.114, a mean
difference score of .2617, with 30 paired observations, the
calculation would be

d =.2617-Jw I 2.114
d = .678

Calculating an effect size from r
Equation 5

d- -

g

See formula use in calculations below for p value and F value conversions.

The results from these formulas are plugged into the formula to calculate an effect size
for r.
Calculating an r from an F-statistic
Equation 6

r=

/Fif
v~

Where df is the error term degree of freedom and there is only 1
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degree of freedom in the interaction term.
Example 4
So, if the F value is given as 3 .175 with 18 degrees of freedom in
the denominator , the calculation would be as follows

r=

3.175
3.175 - 18

r = .462

Using the formula for an effect size conversion for r

d=

4(.462) 2
1- (.462) 2

d = 1.04

Calculating an r from an exact p value
Equation 7

Equation 8
2

(2.515517)(.802853a)(.010328a )
z- a
- [ 1- (1.432788a)(.189269a 2 )(.001308a

]
3

)
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Then insert into the formula for a z value
Example 5
So, if an article presented a p value of .021 (N=60) , then the
calculation would be as follows

a

= -J2267.57

a =

7.7265

[ ___ (2_.5_1_55_1_7_)(_.8
_02_8_5_3 _x_7.
z= .
_72_6_5_)(_.0_l 0_3_2_8_x_5_9._69_8_) __
]
7 7265
1- (1.432788 x 7.7265)(.189269 x 59.698)(.001308 x 461.262)

z = 7.7265 (9.621/-74.41)
z=.99
Then, calculating an r from a z value

r

= .J.99 2 I 60
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r = .127

Using the formula for an effect size from r

4(.127) 2
1- (.127) 2

d=

d = .256
Calculating an effect size for a cross-over study
Equation 9.

d=

Xe-X
SDc-JI -

r ec

2

where

r ec

is the correlation between the experimental and

control. For cross-over studies the correlation is between pre-post because
experimental and control subjects are the same.
Example 6.
If the lowest correlation between pre-post measures is reported to
be or calculated to be .45, experimental mean of3.69 and a control
mean of2.54, A pooled standard deviation of 3.65. (Same numbers
from Example 1.) Results are as follows,

3.69- 254

d=--===

3.65-J1- .45 2

d = 1.15/3.65 (.89)
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d = 1.15/3.25
d = .35

(to note difference adding correlation makes
compare to effect size calculation from Example 1.
where d = .308)

Calculating pooled standard deviations
Equation 10

(nl - l)sl 2 + (n2 - l)s2 2
nI + n2 - 2

Sp=

Example 7
So , if a article presents with a SD for a treatment group of3.44 (N
=

80) and a SD for a control group of3 .85 ( N

=

80), the

calculation would be

Sp=

79(3.44)2 + 79(3.85)

2

79+ 79- 2

Sp= 3.65

Calculating an Odds Ratio
Equation 11

OR

=

ad
be where a = positive outcomes for experimental group , b = positive
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outcomes for control, c = negative outcomes for the experimental group, and d = negative
outcomes from the control groups. a+b+c + d = N.
Example 8.
If an article presents the information that out of 30 experimental

subjects 22 achieved at least a 50% reduction in symptoms and 10
out of 30 in the control group achieved the same criteria, the
calculation would be as follows.

a = 22 , b = 10, c = 8, d = 20

OR =(22 )(20)/(10)(8)
OR = 5.5
Calculating Cochrane's Q
Equation 12.

Qw=

L w(Y,:- µ)

2

where w= the inverse of the variance (or weight) , Yi =

the effect size of each trial , and

µ = the overall effect estimated from the meta-

analysis.
Example 9.
If a meta-analysis is being performed on three studies and effect

sizes have been calculated on continuous data the following
information would be available.
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Study 1

d = .40

variance

=

.11 weight (inverse of the

variance

=

.10 weight (inverse of the

variance) = 9. 5
Study 2

d = .51

variance)
Study 3

d = .51

variance

=

9 .3

.17 weight (inverse of the

=

variance)

=

5.8

If these numbers used to calculate an overall effect size with the
REM model (using Meta-Analysis® computer program) the
population effect size estimate is found to be .47. Using this as the
population estimate of effect a Cochrane's Q can be calculated .

Qw ::: 9.5(.40-.47)

2

+ 9.3(.51-.47)

2

+ 5.8(.51-.47)

2

Qw = 9.5(.0049) + 9.3(.0016)+5.8(.0016)
Qlv =.069
A very small Cochrane's Q which indicates very little variation
between studies.
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Appendix G: Regression Analyses and Correlation
Results for Propranolol

Table GI

Summary of Regression Analysis for Variables Predicting Treatment Outcome Results
for Propranolol

Variable

B

SEB

p

.483

.172

.011

Excluded

B

I

p

Comparison group

.28

.138

.892

Control group type

.188

.999

.330

Length ofTx

-.002

-.008

.994

Outcome measure

-.263

-1.453

.162

Quality score (Jadad)

-.224

-1.196

.246

Quality rating

-.266

-1.431

.168

Mortality rate

-.072

-.378

.710

Percent female

.036

.189

.852

Publication year

.188

.883

.388

Entered
Study type

Note. R 2 =.273, F= 7.89.
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Table G2
Correlation Between Variables and Unbiased Effect Sizes for Propranolol

Variable

Correlation (r) with
unbiased effect size

Variable

Correlation (r) with
unbiased effect size

Comparison group

-.42

Quality rating

-.367

Mortality rate

-.058

Control group type

.080

Length ofTx

-.272

Percent female

-.045

Outcome measure

-.257

Publication year

.109

Quality score( Jadad)

-.308

Study type

.514**

Note.

** Correlation

is significant at that 0.01 level (2-tailed).
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Appendix H: Regression Analyses and Correlation
Results for Flunarizine

Table HI

Summary of Regression Ana lysis for Variables Predicting Treatment Outcome Results
for Flunarizine
Variable

B

SEB

p

.772

.014

.001

B

t

p

Comparison group

-.231

-.232

.243

Control group type

.008

-.037

.971

Outcome measure

-.033

-.167

.871

Quality score (Jadad)

.191

1.019

.330

Quality rating

.320

1.887

.086

Mortality rate

-.130

-.624

.545

Percent female

-299

-1.699

.117

Publication year

-.533

-3.037

.011

.220

1.165

.269

Entered
Treatment length
Excluded

Study type
Note. R2 =.587, F= 17.074.
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Table H2
Correlation Between Variables and Unbiased Effect Sizes for Flunarizine

Correlation (r) with
unbiased effect size

Variable

Correlation (r) with
unbiased effect siz

Comparison group

-.403

Quality rating

-.211

Control group type

.303

Mortality rate

-.417

.733**

Percent female

-.135

Outcome measure

-.182

Publication year

.082 .

Quality score(Jadad)

.061

Study type

.399

Variable

Length of Tx.

Not e. ** Correlation is significant at that 0.01 level (2-tailed).
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Appendix I: Regression Analyses and Correlation
Results for Divalproex Sodium

None of the variables met the inclusionary criteria for a stepwise regression
(F < .05) thus variables were forced in through the enter method to obtain values.

Table II

Summary of Regression Analysis for Variables Predicting Treatment Outcome Results
for Divalproex Sodium
B

SEB

p

B

t

p

Comparison group

NIA

NIA

NIA

Control group

NIA

NIA

NIA

Quality score (Jadad)

-.234

-.627

.564

Quality rating

-.332

-.863

.437

Outcome measure

NIA

NIA

NIA

Mortality rate

-.356

-1.150

.314

Percent female

-.452

-1.376

.241

Publication year

-.037

-.106

.921

Treatment length

4.071

.646

.553

Variable
Entered
None
Excluded

Study type

.324
1.013
.368
Note. R =1.00. Comparison group, control group, and outcome measure deleted from
regression because they were constants or nearly constants could not be computed.
2
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Table 12
Correlation Between Variables and Unbiased Effect Sizes for Divalproex Sodium

Correlation (r) with
unbiased effect size

Variable

Correlation (r) with
unbiased effect size

Comparison group

.72

Quality rating

-.631

Control group type

-.72

Mortality rate

-.168

Length ofTx

-.223

Percent female

-.698

Outcome measure

NIA

Publication year

.165

Quality score
(Jadad)

-.515

Study type

.117

Variable

/

Note. ** Correlation is significant at that 0.01 level (2-tailed). Outcome measure deleted
because it was a constant.
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Appendix ]:Regression Analyses and Correlation
Results for Thermal Biofeedback

None of the variables met the inclusionary criteria for a stepwise regression
(F < .05) thus variables were forced in through the enter method to obtain values.

Table JI
Summary of Regression Analysis for Variables Predicting Treatment Outcome Results
for Thermal Biofeedback
B

SEB

p

B

t

p

Comparison group

-.176

-3.920

.030

Control group type

2.641

.705

.532

Outcome measure

-.233

-2.210

.114

Quality score
(Jadad)

-.686

-3.012

.057

Quality rating

-6.23

-.310

.777

Mortality rate

3.446

-2.357

.100

Percent female

8.011

1.650

.198

Publication year

3.355

.344

.754

Treatment length

8.341

.035

.974

Study type

NIA

NIA

NIA

Variable
Entered
None
Excluded

Note. R2 =.928, F = 3.876. Variable study type removed because is was a constant.
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Table 12

Correlation Between Variables and Unbiased Effect Sizes for Thermal Biofeedback

Variable

Correlation (r) with
unbiased effect size

Variable

Correlation (r) with
unbiased effect size

Comparison group

-.072

Quality rating

-.249

Control group type

.495

Mortality rate

-.222

Length of Tx.

.159

Percent female

-.440
.221

Outcome measure

-.411

Publication year

Quality score
(Jadad)

-.241

Study type

Note. Study type removed because it was a constant.

NIA
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Appendix K: Correlation Tables for Relaxation Therapy

Table Kl

Correlations Between Variables and Unbiased Effect Sizes for Relaxation Therapy

Variable

Correlation (r) with
unbiased effect size

Variable

Correlation (r) with
unbiased effect size

Comparison group

-.603

Quality rating

-.698

Control group type

NIA

Mortality rate

.159

Length ofTx.

.459

Percent female

.057

Outcome Measure

.603

Publication year

-.389

Study type

NIA

Quality score
(Jadad)

-.698

Note . Control group and study type deleted because they are constants.
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Appendix L: Post-Hoc Multiple Comparisons
with Bonferroni Corrections

Table LI

Post-Hoc Comparisons of Treatments for Continuous Effect Sizes

t

Standard error
of the difference

p value

Propranolol vs. Flunarizine

0.000

0.023

1.000

Propranolol vs. Thermal Bio.

3.113

0.026

0.008

Propranolol vs. Relaxation

1.452

0.048

0.157

Propranolol vs. Thermal+ Cog.

0.760

0.053

0.453

Flunarizine vs. Thermal Bio.

2.522

0.032

0.017

Flunairizne vs. Relaxation

1.175

0.060

0.256

Flunarizine vs. Thermal+ Cog.

0.619

0.065

0.544

Thermal vs. Relaxation

2.238

0.067

0.038

Thermal vs. Thermal + Cog.

1.6215

0.074

0.123

Relax vs. Thermal + Cog.

0.196

0.153

0.852

Treatments compared

Note. Bonferroni Correction criteria is p < .005. ANOV AF = 2.9024, p

=

0 .0297.
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Table L2

Post-Hoc Bonferroni Comparisons of Treatments for Continuous Effect Sizes

t

Standard error
of the difference

p value

Propranolol vs. Flunarizine

0.060

0.148

0.562

Propranolol vs. Divalproex Sodium

0.745

0.094

0.475

Propranolol vs. Thermal Bio.

0.000

0.019

1.000

Propranolol vs. EMG Bio.

3.414

0.261

0.014

Propranolol vs.EMG + Thermal Bio.

2.384

0.191

0.048

Flunarizine vs. Divalproex Sodium

0.745

0.215

0.483

Flunarizine vs. Thermal Bio.

0.603

0.149

0.565

Flunarizine vs. EMG Bio.

1.946

0.503

0.1468

Flunarizine vs. EMG + Thermal Bio.

1.012

0.379

0.368

Divalproex Sodium vs. Thermal Bio.

0.210

0.095

0.837

Divalproex Sodium vs. EMG Bio.

2.682

0.339

0.043

Divalproex Sodium vs.
EMG + Thermal Bio.

1.737

0.259

0.132

Thermal Bio. vs. EMG Bio.

3.402

0.262

0.014

Thermal Bio. vs EMG +Thermal Bio.

2.375

0. 198

0.049

EMG Bio. vs. EMG + Thermal Bio.S

2.407

0.565

0.095

Treatments compared

Note. Bonferroni correction criteria is p < .003. ANOVA F = 3.177, p = 0 .314.
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